healthevidencedigest

Author: M Rodriguez, CST/CMA/CCA

  • The FDA Just Published a Safety Roadmap for Gene Editing Therapies. Here Is What the NGS Guidance Actually Covers and Why It Matters.

    The FDA Just Published a Safety Roadmap for Gene Editing Therapies. Here Is What the NGS Guidance Actually Covers and Why It Matters.

    📌 The essentials On April 14, 2026, the FDA’s Center for Biologics Evaluation and Research (CBER) published draft guidance titled “Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing.” What it is: a set of recommendations for how companies developing gene editing therapies should use next-generation sequencing (NGS) methods in nonclinical studies to evaluate safety before starting clinical trials. Who it applies to: sponsors developing both ex vivo (cells edited outside the body, then returned) and in vivo (gene editing directly inside the patient’s tissues) human gene therapy products, submitted in support of IND applications and BLAs. What it addresses: sequencing strategies to detect off-target editing events, methods to assess chromosomal integrity, sample selection, analysis parameters, and reporting requirements. Why it matters: this guidance does not approve any drug. It gives sponsors a standardized, scientifically grounded framework for the safety assessment work that must precede clinical trials, reducing regulatory uncertainty and potentially shortening development timelines. Public comment deadline: July 14, 2026. Docket: FDA-2026-D-1255.

    Gene editing therapies are among the most technically complex and scientifically promising treatments in modern medicine. The ability to make precise changes to the DNA of living cells has already produced approved therapies for conditions that were previously untreatable, including sickle cell disease, beta-thalassemia, and most recently the first gene therapy for genetic deafness. The pipeline is substantial and growing. But the path from a gene editing candidate to an approved therapy requires rigorous safety assessment, and one of the most important questions that must be answered before any gene editing therapy enters human clinical trials is: what happens when the editing tool goes somewhere it was not supposed to go?

    On April 14, 2026, the FDA issued draft guidance specifically addressing how to answer that question. The document provides recommendations for using next-generation sequencing (NGS) methods in nonclinical studies to evaluate safety risks associated with off-target gene editing and loss of genomic integrity. It is a technical document aimed primarily at drug developers and researchers, but the questions it addresses are directly relevant to any patient or family considering a gene therapy clinical trial, and to anyone following the gene therapy field’s trajectory.

    This post covers what off-target editing is and why it is a safety concern, how NGS is used to detect it, what the guidance specifically recommends, and why this particular regulatory step matters for the field.

    The Problem the Guidance Is Solving: Off-Target Editing

    To understand why this guidance exists, it helps to understand the specific risk it is designed to evaluate.

    How gene editing works

    Gene editing technologies, the most widely discussed being CRISPR-Cas9, work by directing a molecular complex to a specific sequence in the genome, where it makes a targeted cut or modification. In most therapeutic applications, the goal is to correct a harmful mutation, disrupt a disease-causing gene, or insert a therapeutic gene into a specific location.

    The molecular machinery that performs this editing uses a guide sequence to find its target in the genome. The human genome contains roughly 3 billion base pairs. The guide sequence is designed to match a unique target, but no biological system is perfect. In some cases, the editing complex finds and modifies sites in the genome that are similar in sequence to the intended target but are not the target. These unintended modifications are called off-target edits.

    Why off-target edits are a safety concern

    The consequences of off-target edits depend entirely on where they occur in the genome. Many genomic locations are non-functional or contain genes with no role in cell survival or proliferation. An off-target edit in one of these locations may have no detectable consequence. But the genome also contains tumor suppressor genes, proto-oncogenes, and genes that regulate cell cycle progression. An off-target edit that disrupts a tumor suppressor or activates an oncogene could, in theory, initiate a process leading to cancer. This is not a theoretical concern invented by regulators: insertional mutagenesis, a related phenomenon in early viral gene therapy, caused leukemia in several patients in early trials in the 2000s, which fundamentally shaped how the field approaches vector safety.

    A separate but related concern is chromosomal integrity. Gene editing tools make cuts in DNA. When the cellular repair machinery processes these cuts, it can sometimes cause larger structural changes: translocations (pieces of one chromosome joining to another), deletions spanning larger regions, or chromosomal rearrangements. These structural changes are assessed separately from single-site off-target edits and require different detection methods.

    The FDA guidance addresses both categories of risk.

    What Next-Generation Sequencing Is and Why It Is the Right Tool

    Next-generation sequencing (NGS), also called high-throughput sequencing, refers to a family of technologies that can read millions or billions of short DNA sequences simultaneously. Unlike the original Sanger sequencing approach, which reads one sequence at a time, NGS generates massive parallel data that can characterize the entire genome of a sample at very high depth, meaning each region is read many times to detect even rare variants.

    This depth of coverage is what makes NGS the right tool for detecting off-target editing. Off-target edits may occur in only a small fraction of cells in a treated sample, perhaps 0.1% or less of the total. Detecting these rare events requires reading each genomic region thousands of times to achieve sufficient statistical confidence that a signal is real rather than a sequencing error. The guidance specifically addresses the sequencing depth required for adequate detection of low-frequency off-target events.

    NGS is also used for assessing chromosomal integrity. Whole genome sequencing and structural variant analysis can detect larger chromosomal rearrangements that would be missed by targeted approaches.

    Short-read versus long-read sequencing

    One of the more technically nuanced aspects of the guidance is its discussion of sequencing strategy. Not all off-target events are the same size:

    Short stretches of DNA change at off-target sites (insertions, deletions, or base substitutions spanning a few to tens of base pairs) are well-characterized by short-read sequencing, where each read covers approximately 150 to 300 base pairs. This is the most widely used NGS approach.

    Longer structural changes (larger deletions, translocations, inversions) may require long-read sequencing approaches, where individual reads span thousands to tens of thousands of base pairs, allowing the detection of events that short-read approaches might miss or mischaracterize.

    The guidance advises sponsors to match their sequencing strategy to the type of event being evaluated, rather than applying a single approach to all safety questions. This is a scientifically rigorous position that acknowledges the genuine methodological trade-offs in the field.

    What the Guidance Specifically Recommends

    The draft guidance covers four main areas: sequencing strategies, sample selection, analysis parameters, and reporting.

    Sequencing strategies

    Sponsors should use sequencing approaches appropriate to the type of off-target event being assessed. For detection of small insertions and deletions (indels) at off-target sites, short-read approaches are generally appropriate. For detection of larger structural variants and chromosomal integrity assessment, long-read approaches or complementary methods such as optical genome mapping should be considered.

    The guidance also addresses sequencing depth, recommending that sequencing be performed at a depth sufficient to detect off-target editing events that may occur at frequencies substantially lower than the on-target edit rate. Because off-target events are typically rare relative to on-target edits, inadequate sequencing depth can produce false-negative results that miss biologically relevant events.

    Sample selection

    The cells selected for safety assessment should reflect the actual therapeutic product. For ex vivo therapies (where cells are edited outside the body and then infused), the edited cell product itself is the appropriate test material. For in vivo therapies (where the editing tool is delivered directly into the patient), selecting appropriate tissue types for safety assessment is more complex and requires consideration of the delivery route and target tissues.

    The guidance acknowledges that for individualized therapies, including personalized therapies being developed for patients with ultra-rare diseases where the specific mutation is unique to one individual, sample availability may be limited. It provides recommendations for how to approach safety assessment in these constrained scenarios.

    Analysis parameters and bioinformatics

    The guidance addresses how sponsors should approach the computational side of NGS analysis. Raw sequencing data must be processed through bioinformatics pipelines to identify candidate off-target sites, filter sequencing artifacts, and determine which signals represent genuine editing events. The document recommends that sponsors provide sufficient detail about their bioinformatics workflows to allow the FDA to evaluate the rigor of the analysis.

    It also addresses how to identify candidate off-target sites to examine in the first place. Computational tools can predict likely off-target sites based on sequence similarity to the guide RNA target, and experimental methods such as GUIDE-seq and CIRCLE-seq can empirically identify editing sites in cell-based systems before sequencing. The guidance recommends using both approaches in combination.

    Reporting

    The guidance specifies what sponsors should include in their IND and BLA submissions regarding off-target safety assessment. This includes the complete list of candidate off-target sites evaluated, the sequencing methodology and depth, the bioinformatics pipeline used, the results at each evaluated site, and a risk assessment framework for interpreting any off-target events detected.

    The Regulatory Context: Where This Guidance Fits

    This is not the FDA’s first guidance document on gene editing safety. It builds directly on January 2024 guidance on human gene therapy products incorporating genome editing, which addressed broader nonclinical, clinical, and CMC considerations. The April 2026 draft guidance goes deeper specifically on the NGS methodology question, providing the technical detail that was implicit but not fully specified in the 2024 document.

    It also relates to FDA’s February 2026 draft guidance supporting approval of ultra-rare disease therapies, which specifically addresses genome editing and RNA-based therapies including antisense oligonucleotides for conditions affecting so few patients that conventional randomized trial designs are not feasible. The NGS safety guidance applies in those individualized therapy contexts as well, and the February guidance specifically cited it.

    The broader policy context is the current administration’s stated priority of accelerating gene therapy development. FDA Commissioner Marty Makary stated at the April 14 release that the guidance provides sponsors with clear, scientifically grounded recommendations for evaluating off-target editing risks using state-of-the-art sequencing technologies and that the agency is serious about moving this ball forward. CBER Director Vinay Prasad described the document as giving sponsors a roadmap for comprehensive safety assessment while supporting the efficient development of these promising therapies.

    The practical significance is reduced regulatory uncertainty. Before standardized guidance existed, different sponsors might approach NGS-based off-target assessment very differently, leading to unpredictable FDA feedback and development delays. A clear framework means sponsors can design their safety assessment programs with confidence that the approach will be acceptable to regulators, potentially saving months of back-and-forth early in development.

    Why This Matters for Patients and the Gene Therapy Field

    Gene editing safety assessment is not a topic that patients following the field need to understand in technical detail. But the existence and quality of this guidance matters for several reasons that are directly relevant to anyone with a personal stake in gene therapy development.

    Faster paths to clinical trials. The guidance is specifically designed to help sponsors design adequate nonclinical studies so that IND applications can move forward without extended regulatory delays. For a patient with a genetic disease watching a promising therapy move through development, regulatory efficiency at the nonclinical stage is a meaningful factor in how quickly human trials begin.

    Individualized therapies for ultra-rare diseases. The guidance explicitly addresses scenarios where standard approaches cannot be fully applied because the patient population is too small to generate conventional safety datasets. This is directly relevant to the growing number of individualized gene therapy programs, some designed for single patients, where regulatory flexibility and clear scientific standards are both necessary.

    The off-target safety question is real. For anyone following the first-in-class gene therapy approvals, including Casgevy (exagamglogene autotemcel) for sickle cell disease and Otarmeni for genetic deafness (covered in our post on the first gene therapy for deafness), understanding that rigorous off-target safety assessment underlies every approved gene editing therapy is reassuring context for both patients and families. This guidance represents the standardization of that rigor across the field.

    Transparency through public comment. As a draft guidance, this document is open for public comment through July 14, 2026. Comments can be submitted via Regulations.gov using docket number FDA-2026-D-1255. Academic researchers, patient advocacy organizations, and industry sponsors are all invited to provide feedback that will inform the final guidance. Organizations like the Alliance for Regenerative Medicine and the American Society of Gene and Cell Therapy (ASGCT) will likely submit formal comments representing the field’s collective perspective.

    What This Guidance Does Not Do

    Clarity on scope matters. This guidance does not:

    • Approve any gene editing therapy or change the status of any existing approved therapy
    • Replace the 2024 genome editing guidance, which it supplements rather than supersedes
    • Address clinical study design, patient safety monitoring during trials, or post-approval safety requirements
    • Apply to non-genome editing gene therapies (such as AAV gene replacement without editing) except where editing tools are used
    • Establish a lower bar for approval; it specifies what evidence is needed, not a reduced standard

    The guidance is specifically about the nonclinical safety assessment phase: the studies done before human trials begin. Clinical trial safety monitoring, informed consent, adverse event reporting, and post-approval pharmacovigilance are governed by separate frameworks.

    Are you a researcher, sponsor, or patient advocate who wants to comment on the draft guidance?

    The comment period closes July 14, 2026. Comments can be submitted electronically at Regulations.gov, docket FDA-2026-D-1255. The full draft guidance document is available at FDA.gov. The FDA also encourages sponsors to engage early through INTERACT meetings and pre-IND meetings to discuss specific development strategies before formal submission.

    For patients and families following gene therapy development, the National Human Genome Research Institute, the American Society of Gene and Cell Therapy, and the Alliance for Regenerative Medicine maintain current information on approved and investigational gene editing therapies.

    Sources

    FDA press announcement: FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development. FDA.gov. April 14, 2026.

    Draft guidance document: Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry. FDA.gov.

    Federal Register docket: FDA-2026-D-1255. Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing. Federal Register. April 15, 2026.

    RAPS coverage: FDA drafts guidance on using next-generation sequencing to assess gene therapy safety. raps.org. April 2026.

    BioSpace coverage: FDA bolsters bespoke therapy framework with new draft safety guidelines. biospace.com. April 2026.

    Clinical Trials Arena: FDA shares guide on genome editing best practices. clinicaltrialsarena.com. April 2026.

    European Pharmaceutical Review: New FDA draft guidance to enhance safety of genome editing therapies. europeanpharmaceuticalreview.com. April 2026.

    January 2024 predecessor guidance: Human Gene Therapy Products Incorporating Human Genome Editing. FDA.gov. January 2024.

    February 2026 ultra-rare disease guidance: Considerations for the Development of Individualized Antisense Oligonucleotide and Genome Editing Therapies. FDA.gov. February 2026.

    Comment submission: Regulations.gov docket FDA-2026-D-1255.

    Patient and researcher resources: National Human Genome Research Institute: Gene Therapy | American Society of Gene and Cell Therapy | Alliance for Regenerative Medicine | FDA INTERACT meetings

    Disclaimer: Health Evidence Digest provides general information about FDA regulatory guidance and health research for educational purposes. This document is a draft guidance, not a final rule, and does not constitute final agency policy until published in final form. This content is not a substitute for professional regulatory, legal, or medical advice. Sponsors developing gene therapy products should consult directly with the FDA through formal meeting procedures regarding specific development programs.
  • Tavneos (Avacopan) and Serious Liver Injury: What Patients and Clinicians Need to Know, Including What the FDA Isn’t Saying Publicly

    Tavneos (Avacopan) and Serious Liver Injury: What Patients and Clinicians Need to Know, Including What the FDA Isn’t Saying Publicly

    ⚠️ Key Safety Summary: Read This First On March 31, 2026, the FDA issued a Drug Safety Communication identifying 76 cases of drug-induced liver injury (DILI) linked to Tavneos (avacopan), including 8 deaths and 54 hospitalizations. Seven biopsy-confirmed cases involved vanishing bile duct syndrome (VBDS), a potentially irreversible liver condition, and 3 of those were fatal. Median time from starting Tavneos to liver injury onset: 46 days. Most cases occurred within 60 days. Updated monitoring requirements: Patients on Tavneos should have liver function tests every 2 weeks for the first month, then monthly for 5 months. Discontinue immediately if ALT/AST exceed 3 times the upper limit of normal (ULN) or ALP exceeds 2 times ULN. Critical context: The FDA had already requested in January 2026 that Amgen voluntarily withdraw Tavneos from the U.S. market. Amgen refused. The drug remains available.

    This story is more complicated than a standard FDA drug safety alert. Tavneos (avacopan) was already under significant regulatory pressure when the March 31, 2026 safety communication was issued, and understanding why the drug is still on the market requires knowing the full context, not just the liver injury numbers.

    The liver injury signal is real and serious. Eight people have died. But the situation patients and clinicians are navigating is also one in which a manufacturer has declined a federal request to remove a drug from shelves, both U.S. and European regulators are reviewing the integrity of the clinical trial data that supported the drug’s original approval, and a major watchdog organization is publicly challenging the FDA’s failure to escalate. All of this is happening while people with a serious, life-threatening autoimmune disease continue to be treated with, and in some cases depend on, the drug in question.

    Here is the whole picture.

    The Disease Tavneos Treats: ANCA-Associated Vasculitis

    ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases in which the body’s immune system attacks and destroys small-to-medium blood vessels throughout the body. The two forms Tavneos is approved to treat are granulomatosis with polyangiitis (GPA, formerly called Wegener’s granulomatosis) and microscopic polyangiitis (MPA).

    These are serious diseases. Untreated or inadequately managed, they can destroy kidney function, damage the lungs, and be fatal. The standard treatment for decades has involved high-dose glucocorticoids (steroids) combined with immunosuppressants such as cyclophosphamide or rituximab. These regimens work, but carry significant toxicity of their own. Chronic steroid use is associated with infection, bone loss, diabetes, and cardiovascular disease. Any therapy that could reduce steroid burden while maintaining disease control represents a genuine clinical advance.

    Avacopan works by blocking the complement C5a receptor, which plays a role in driving neutrophil-mediated inflammation in AAV. The ADVOCATE Phase 3 trial showed it could achieve non-inferior remission rates compared with prednisone tapering at week 26, and superior sustained remission at week 52, with significantly less glucocorticoid exposure. Published in the New England Journal of Medicine in 2021, those results drove FDA approval. That is a clinically meaningful result for a disease where the side effects of standard treatment are themselves a major burden.

    The Liver Injury Signal: What the Data Shows

    Hepatotoxicity, meaning drug-induced liver injury, was not a surprise finding with avacopan. It was identified in premarket clinical trials and included in the drug’s prescribing information as a warning from the time of approval in 2021. In the ADVOCATE trial itself, 5.4% of patients in the avacopan arm experienced serious adverse events related to liver function, compared with 3.6% in the prednisone arm.

    What changed, and what the March 31, 2026 safety communication addresses, are two new and more severe categories of concern that emerged in the postmarketing period:

    CategoryNumber of CasesOutcomes
    All DILI cases (reasonable causal evidence)76 total74 serious outcomes
    Hospitalizations54—
    Deaths8All fatal by definition
    Cholestatic or mixed injury pattern38 of 60 with lab dataElevated ALP + bilirubin
    Biopsy-confirmed VBDS7All hospitalized; 3 fatal
    Median time to onset46 daysRange: 22 to 140 days
    Cases from Japan66 of 76Largest concentration globally

    Source: FDA Drug Safety Communication. March 31, 2026.

    What is vanishing bile duct syndrome (VBDS)? VBDS is a rare and serious condition in which the small bile ducts inside the liver are progressively destroyed. Bile, the digestive fluid produced by the liver, can no longer drain properly, leading to a backup of bile acids in the liver and bloodstream. It is called “vanishing” because on liver biopsy, the small intrahepatic bile ducts that are normally present in portal tracts have disappeared. The resulting damage can be permanent and may eventually progress to cirrhosis or liver failure if not caught early. VBDS is most commonly caused by drug-induced liver injury, immune-mediated disorders, infections, and malignancy. It is distinctly different from the transient transaminase elevations seen in many drug reactions. It is a structural injury to the bile duct architecture itself. Clinically, patients typically present with jaundice (yellowing of skin or eyes), pruritus (intense itching that is often worse at night), and fatigue. In the avacopan VBDS cases, the majority occurred within 60 days of starting treatment.

    Why Are 87% of Cases From Japan?

    The geographic concentration of DILI and VBDS cases is one of the most striking features of this safety signal. Of 76 total DILI cases, 66 were reported from Japan, approximately 87%. Of the 7 biopsy-confirmed VBDS cases, 6 were from Japan.

    Amgen has noted that VBDS cases from Japan primarily involved patients aged 65 and older. Several factors may contribute to the geographic pattern, none of which are definitively established:

    Pharmacogenomic differences: Japanese patients may have different expression profiles or activity levels for the drug-metabolizing enzymes responsible for avacopan clearance, potentially altering hepatic drug exposure.

    AAV epidemiology: MPA is substantially more prevalent in Japan than GPA compared with Western countries, and the two conditions may involve different baseline inflammatory profiles affecting hepatic susceptibility.

    Concomitant medications: Patients in Japan may more frequently receive certain co-medications. Antibiotics such as trimethoprim/sulfamethoxazole, commonly given as infection prophylaxis in immunocompromised patients, have themselves been associated with DILI and may interact synergistically.

    Post-marketing surveillance intensity: Japan has a notably rigorous pharmacovigilance system, and some of the apparent geographic concentration may reflect more systematic case capture rather than true biological difference.

    Age and comorbidity profile: The older age of most Japanese VBDS cases may reflect a population with greater baseline hepatic vulnerability.

    A case report published in Annals of Internal Medicine: Clinical Cases documented VBDS in a 74-year-old patient with MPA treated with avacopan, with a Naranjo Adverse Drug Reaction score of 6 (probable causality). That report noted the importance of monitoring compliance: in that case, liver enzyme testing had been inadvertently delayed, which may have contributed to the severity of the injury. It also noted that prior DILI episodes may increase vulnerability to subsequent drug-related liver injury.

    The Bigger Story: FDA Requested Withdrawal. Amgen Said No.

    The March 31 safety communication cannot be read in isolation. Six weeks earlier, on January 16, 2026, the FDA had privately requested that Amgen voluntarily withdraw Tavneos from the U.S. market. Amgen disclosed this publicly in February, and on January 28 formally informed the FDA it would not comply.

    The FDA’s withdrawal request cited two concerns. The first was hepatotoxicity, specifically the emerging DILI and VBDS signal that became the subject of the March safety communication. The second was a data integrity issue: the FDA raised questions about a process followed by ChemoCentryx (the original developer) to re-adjudicate primary endpoint results for 9 of the 331 patients in the ADVOCATE trial, the sole pivotal study supporting avacopan’s approval.

    What was the ADVOCATE endpoint re-adjudication controversy? The ADVOCATE trial used the Birmingham Vasculitis Activity Score (BVAS) to assess disease activity. The primary endpoint was remission (BVAS = 0) at week 26. After investigators originally scored certain patients, a post-hoc adjudication committee reviewed and changed the scores for 9 patients. The FDA first raised concerns about this process during the original 2021 review, and the FDA advisory committee vote on avacopan’s approval was close. These disputes were later publicly aired in a civil investor lawsuit (Amgen won in August 2025) and triggered the EMA’s January 2026 safety review of avacopan in Europe. The ADVOCATE re-adjudication issue is about whether the efficacy data supporting avacopan’s approval was handled appropriately, specifically whether changing endpoint scores for 9 patients affected the trial’s outcome assessment in ways that could have influenced regulatory decisions.

    Amgen’s response has been consistent: the company maintains that Tavneos has a favorable benefit-risk profile, that liver toxicity is a known and labeled risk, and that more than 7,000 patients have been treated with it since approval. The company has indicated it submitted a proposed label update to the FDA in 2024 to add VBDS to the prescribing information, a request that was still pending at the time of the March 31, 2026 safety communication.

    It is also contextually relevant that Tavneos generated $459 million in sales in 2025, growing 62% year-over-year, making it one of Amgen’s fastest-growing products. That commercial context is not dispositive in evaluating Amgen’s position, but it is part of the full picture of why a voluntary withdrawal request would face resistance.

    Dr. Robert Steinbrook, Health Research Group Director at Public Citizen, stated in a formal release on March 31, 2026 that if the FDA in January 2026 requested that avacopan be voluntarily withdrawn from the U.S. market, the agency needed to explain publicly why it had not made that request publicly, and why the prescribing information did not yet include a boxed warning for the risk of fatal liver disease. He characterized these as urgent questions for the FDA to answer.

    That criticism represents a legitimate and so far unanswered question about regulatory transparency. The FDA’s standard tools when a company declines voluntary withdrawal are limited: the agency can initiate mandatory withdrawal proceedings, but these require formal regulatory steps and take time, and no such proceedings have been announced.

    For Patients Currently Taking Tavneos

    If you are taking Tavneos for ANCA-associated vasculitis, the most important message is this: do not stop the medication on your own without speaking to your rheumatologist first. Stopping avacopan abruptly without a transition plan in a patient with active GPA or MPA could allow disease flare, which carries its own serious risks including kidney damage.

    Symptoms of liver injury: seek care immediately if you develop any of these Unusual fatigue or weakness that is more than your baseline; nausea or vomiting without another clear cause; itching (pruritus), especially if persistent or worse at night; yellowing of your skin or the whites of your eyes (jaundice); light-colored or pale stools; dark, tea-colored urine; pain or swelling in the upper right abdomen. These symptoms can appear within the first six weeks of treatment. Do not wait for your next scheduled appointment. Contact your provider the same day.

    If you have concerns about whether to continue Tavneos given the safety communication, that conversation belongs with your rheumatologist specifically. The benefit-risk calculation is individual: it depends on your disease severity, how well your vasculitis is controlled, your liver function baseline, and whether alternative regimens are viable for your situation. The Vasculitis Foundation has issued a patient-facing update on this situation and is a good resource for community support and current information.

    Adverse events should be reported to FDA MedWatch at 1-800-332-1088 or online at fda.gov/safety/medwatch.

    For Clinicians: Monitoring Protocol and Decision Framework

    The FDA’s updated monitoring recommendations are specific and represent an intensification of the original labeling:

    Time PeriodMonitoring FrequencyAction Threshold
    First month of treatmentEvery 2 weeksDiscontinue if ALT/AST greater than 3 times ULN, or ALP greater than 2 times ULN
    Months 2 to 6MonthlySame thresholds; monitor for new symptoms
    After 6 monthsAs clinically indicatedRemain vigilant for late-onset cases
    Any timeImmediately on symptomsJaundice or pruritus: discontinue and refer to hepatology

    Key clinical judgment points for prescribers:

    The DILI pattern in most cases is cholestatic or mixed, characterized by elevated alkaline phosphatase (ALP) and total bilirubin rather than isolated transaminase elevation. This pattern can progress more insidiously than hepatocellular injury. Do not wait for transaminase elevation alone to act.

    VBDS is a structural, potentially irreversible injury. If a patient develops jaundice or persistent pruritus, discontinue avacopan promptly and refer to hepatology without waiting to see if liver enzymes normalize on repeat testing.

    Prior DILI episodes from any cause may increase susceptibility to subsequent drug-induced liver injury. Take a thorough medication and hepatic history before initiating avacopan.

    The median onset of 46 days means the highest-risk window falls exactly in the first two months. The biweekly monitoring in month one is not optional in the current regulatory and clinical context.

    Document your monitoring compliance carefully. The published VBDS case report noted that a two-week delay in scheduled liver monitoring may have contributed to injury severity in that patient.

    For patients with uncontrolled disease where avacopan provides meaningful clinical benefit, the benefit-risk calculation may still favor continuation with rigorous monitoring. For patients in stable remission or with other viable options, the calculus is different. Consult ACR vasculitis guidelines and consider hepatology co-management when initiating or continuing therapy given the current safety signal.

    What Happens Next

    EMA review

    The European Medicines Agency launched a review of avacopan in January 2026, citing concerns about data integrity in the ADVOCATE trial. The EMA will evaluate all available evidence to determine whether the handling of trial data affects the overall benefit-risk profile of avacopan for European patients. That review is ongoing.

    FDA mandatory withdrawal authority

    When a pharmaceutical company declines a voluntary withdrawal request, the FDA can initiate mandatory withdrawal proceedings under 21 U.S.C. §355(e), but this requires a formal process that includes opportunity for hearing. The FDA has not announced it is pursuing this path for avacopan. Whether and when the agency escalates remains an open question.

    Label update (pending)

    Amgen submitted a proposed label update in 2024 to add VBDS to the prescribing information. As of the March 31, 2026 safety communication, that label change had not yet been approved. The current label includes a hepatotoxicity warning but does not specifically mention VBDS by name.

    Boxed warning

    Public Citizen has called for a boxed warning, the FDA’s strongest label alert, reserved for serious or life-threatening risks, for fatal liver disease associated with avacopan. The current label does not carry a boxed warning for hepatotoxicity. Given eight confirmed deaths, the question of whether the FDA will move in this direction in any eventual label update bears watching.

    For related coverage of how FDA regulatory tools, including drug safety communications, mandatory withdrawal authority, and label change procedures, work in practice, see our earlier post on what the FDA’s contrasting decisions on camizestrant and vepdegestrant reveal about regulatory evidence standards.

    If you are a patient or caregiver navigating this situation:

    The Vasculitis Foundation is actively tracking developments and providing patient-centered guidance on the Tavneos situation. The American College of Rheumatology maintains current treatment guidelines for AAV. Adverse events can be reported directly to the FDA MedWatch system at 1-800-332-1088 or online.

    Sources

    FDA Drug Safety Communication: FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (avacopan). March 31, 2026. fda.gov.

    Tavneos original FDA approval: FDA approves avacopan for ANCA-associated vasculitis. October 7, 2021. fda.gov.

    Amgen prescribing update: Important Update Regarding TAVNEOS (avacopan). Amgen. April 2026.

    ADVOCATE Phase 3 trial: Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med. 2021;384:599-609.

    ADVOCATE trial registration: NCT02994927. ClinicalTrials.gov.

    VBDS case report: Annals of Internal Medicine: Clinical Cases. Avacopan Causing Vanishing Bile Duct Syndrome in an Adult Patient With Microscopic Polyangiitis. 2024. doi:10.7326/aimcc.2024.0602

    Withdrawal controversy: Medscape. What’s at Issue in the FDA’s Request to Withdraw Avacopan? February 23, 2026.

    Medscape alert coverage: Medscape. FDA Issues Alert on Liver Injuries Linked to Vasculitis Drug, Following Withdrawal Request. March 31, 2026.

    Amgen refusal: Pharmaphorum. Amgen baulks at FDA request to withdraw Tavneos. February 2026.

    Public Citizen statement: Public Citizen. FDA’s Avacopan Alert Raises More Questions Than It Answers. March 31, 2026.

    EMA review: European Medicines Agency. EMA starts review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA. January 30, 2026.

    Vasculitis Foundation patient update: Important Information for the Vasculitis Community Regarding TAVNEOS (avacopan). vasculitisfoundation.org. April 2026.

    The Rheumatologist: Kaufman MB. Avacopan Under Scrutiny by FDA, EMA Due to Data Concerns. February 21, 2026. the-rheumatologist.org.

    ACR vasculitis guidelines: American College of Rheumatology. Guidelines for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. rheumatology.org.

    MedWatch adverse event reporting: FDA MedWatch Safety Reporting Portal. fda.gov/safety/medwatch.

    Patient resources: Vasculitis Foundation | American College of Rheumatology | FDA MedWatch | NIAMS Vasculitis Information

    Disclaimer: Health Evidence Digest provides general information about drug safety communications and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Patients should not make changes to their medication without consulting their healthcare provider. All clinical decisions should account for individual patient circumstances, disease severity, and current treatment guidelines.
  • One in Three Women with Premature Ovarian Insufficiency Gets the Hormone Therapy They Need. Here Is Why That Number Should Be Much Higher.

    One in Three Women with Premature Ovarian Insufficiency Gets the Hormone Therapy They Need. Here Is Why That Number Should Be Much Higher.

    📌 The essentials A study published in Menopause, the journal of The Menopause Society, analyzed data from more than 255,000 patients and found that only 36% of women diagnosed with premature ovarian insufficiency (POI) received hormone therapy, despite consistent international guidelines recommending it. The study was conducted in tertiary hospitals in Saudi Arabia, providing real-world prescribing data from a region where HT underuse is documented but less studied. The gap matters because women with POI who do not receive hormone therapy until the average age of natural menopause face substantially higher risks of osteoporosis, cardiovascular disease, cognitive decline, and mood disorders compared with women who reach menopause naturally after age 40. The finding is consistent with what the NIH and multiple research groups have documented in U.S. and European populations: HT underuse in POI is a global problem, not a regional one.

    Premature ovarian insufficiency is not the same as early menopause, though the terms are often used interchangeably. It is a clinical diagnosis made when a woman loses normal ovarian function before the age of 40, with ovarian function sometimes fluctuating rather than ceasing entirely. About 1 in 100 women is affected. Many are in their 20s and 30s. Some are teenagers. Most receive a diagnosis only after months or years of being told their irregular periods are stress, overexercise, or a thyroid issue.

    When the diagnosis finally arrives, it carries consequences that extend well beyond infertility, which tends to dominate the conversation. Women with POI face the same estrogen deficiency that women in natural menopause experience, but they face it decades earlier, and they face it for far longer. The cumulative health burden of that estrogen deficit over 10 to 20 additional years is substantial, and it is largely preventable with hormone therapy.

    A new study published in Menopause in January 2026 quantifies how large the treatment gap actually is. Only 36% of women diagnosed with POI received hormone therapy. That means roughly two out of three women with a condition that consistently generates international guideline recommendations for HT are not getting it.

    What POI Is and Why It Is Different from Natural Menopause

    Premature ovarian insufficiency is defined by two criteria: age younger than 40, and biochemical confirmation of ovarian dysfunction, typically elevated follicle-stimulating hormone (FSH) levels on two measurements taken at least four weeks apart. The ovaries have not failed completely in most cases. Intermittent ovarian activity and even spontaneous pregnancy can occur in 5 to 10% of women after diagnosis. But sustained, predictable hormone production has been disrupted.

    The distinction from natural menopause matters for treatment and prognosis. In natural menopause, the gradual decline in estrogen production reflects a process that unfolds over the expected lifespan, and cardiovascular, bone, and neurological systems have had decades to adapt. In POI, the estrogen deficit arrives abruptly and at an age when those systems have not yet had that adaptation. The resulting long-term risks are not equivalent.

    The long-term health consequences of untreated POI Bone: Osteoporosis risk is substantially elevated in women with POI, driven by the loss of estrogen’s protective effect on bone mineral density. Women with POI have significantly lower bone density than age-matched peers, and the risk of fragility fractures accumulates with each decade of untreated estrogen deficiency. Even in the study reviewed here, which found that 6.8% of participants had a documented diagnosis of osteopenia and 4.9% had osteoporosis, hormone therapy uptake in those women remained low. Cardiovascular: Estrogen has cardioprotective effects, and its premature loss is associated with higher rates of cardiovascular disease, hypertension, and adverse lipid profiles in women with POI compared with age-matched controls. Women with POI who do not receive HT have been shown to have cardiovascular risk profiles closer to those of age-matched men than to age-matched women who entered menopause at the expected time. Cognitive and neurological: There is growing evidence that estrogen plays a role in brain health and cognitive function, and some studies suggest increased risk of cognitive decline and dementia in women with untreated POI. The mechanism is not fully established, but the long window of estrogen deficiency is a plausible contributor. Mood and mental health: Depression, anxiety, and sexual dysfunction occur at higher rates in women with POI than in age-matched controls. Estrogen has direct effects on neurotransmitter systems involved in mood regulation, and the psychological burden of the diagnosis itself, including grief over fertility loss and uncertainty about long-term health, compounds the biological effects.

    What the Study Found

    The study, published in the January 2026 issue of Menopause, was conducted across tertiary hospitals in Saudi Arabia. Researchers analyzed data from more than 255,000 patients with the objective of determining how often hormone therapy is prescribed for women with POI and what factors are associated with receiving it.

    Key findings:

    The prevalence of POI among women who underwent FSH testing was 5.05%. This is higher than the 3.5% global estimate from prior systematic reviews, though the difference likely reflects selection bias: women being tested for FSH in tertiary settings are more likely to have symptoms suggestive of ovarian dysfunction than the general population.

    Of women diagnosed with POI, only 36% received hormone therapy. That is the central number, and it is consistent with underuse estimates from other regions. A previous systematic review found that across multiple countries, hormone therapy initiation rates in women with POI range from approximately 35 to 50%, with wide variation based on geography, healthcare system, and provider specialty.

    Amenorrhea (absence of menstrual periods) was the most common presenting symptom, affecting 42.4% of participants. This is clinically important context: amenorrhea is the symptom most likely to prompt FSH testing and subsequent POI diagnosis, but it is also a symptom that can persist for years without triggering a formal workup in healthcare systems where irregular periods are routinely attributed to stress, thyroid dysfunction, or other causes.

    Hormone therapy uptake remained low even in the subset of women who already had a documented diagnosis of bone density loss: 6.8% with osteopenia and 4.9% with osteoporosis were identified in the cohort, and HT use remained below expected rates in these groups. This finding is particularly striking because bone protection is one of the most clearly established benefits of HT in POI and one where the risk-benefit calculation most clearly favors treatment.

    Geographic context: This study was conducted in Saudi Arabia, and regional differences in hormone therapy use are well established and real. Cultural, religious, and healthcare system factors influence prescribing patterns in ways that limit direct extrapolation. However, the authors note that the NIH and multiple U.S.-based research groups have documented comparably low HT utilization in American women with POI, and the ESHRE POI guideline explicitly addresses the underuse problem as a global phenomenon.

    The WHI Shadow: Why Fear of Hormone Therapy Has Outlasted the Evidence That Created It

    To understand why two-thirds of women with POI are not receiving a treatment that guidelines consistently recommend, you need to understand what happened in 2002.

    The Women’s Health Initiative (WHI) was a large, landmark study of hormone therapy in postmenopausal women. In 2002, the combined estrogen-progestin arm of the trial was stopped early after researchers found increased risks of breast cancer, heart disease, stroke, and blood clots. The results generated enormous media coverage and fundamentally shifted prescribing behavior. HT use in menopausal women plummeted within months and has never fully recovered.

    The problem is that the WHI findings were widely misapplied. The study enrolled women with an average age of 63, the majority of whom were more than 10 years past menopause. The findings were about hormone therapy initiated years after menopause in women for whom estrogen replacement was not restoring a physiological state but adding hormones to a body that had long since adapted to their absence. The results do not apply to women in their 20s and 30s with POI, in whom HT is restoring estrogen levels to what would naturally be present at their age.

    Major medical organizations have tried to correct this misapplication. The Menopause Society’s 2023 position statement explicitly states that for women younger than 40 with POI, HT is recommended until the average age of natural menopause (approximately 51) in the absence of contraindications, and that the risks identified in the WHI do not apply to this population. The ESHRE POI guideline, the NICE guideline on menopause, and the Royal Australian and New Zealand College of Obstetricians and Gynaecologists all say the same thing.

    The message has not reached clinical practice consistently, and it has reached patients even less.

    What the Guidelines Actually Say

    International clinical guidelines on POI are consistent in their core recommendation: hormone therapy should be offered to women with POI until approximately the average age of natural menopause, roughly 51 years in most populations, unless there is a specific contraindication.

    The rationale is straightforward. HT in POI is not pharmacological intervention in the way that HT in a 60-year-old is. It is replacement of hormones that the body would naturally be producing at that age but is not. The risks associated with HT in older postmenopausal women do not apply because the frame of reference is different: POI in a 28-year-old is not the same biological situation as menopause in a 63-year-old.

    The specific formulation of HT in POI is also distinct from what is typically used in natural menopause. Estrogen doses needed to restore physiological levels in women with POI are generally higher than standard low-dose HT formulations used in natural menopause. Many standard preparations are designed for symptom management in older postmenopausal women at the lowest effective dose. Women with POI need estrogen levels comparable to what their peers have naturally, which may require different dosing strategies and routes of administration.

    Women with an intact uterus also need progestogen to protect the uterine lining from unopposed estrogen stimulation. The choice of progestogen formulation matters: micronized progesterone (body-identical progesterone) appears to carry a lower breast cancer risk signal than synthetic progestins based on current evidence, though the absolute risk differences in young women are small.

    Barriers to Treatment: What the Research Points To

    The study’s authors identify two primary drivers of HT underuse in POI: provider knowledge gaps and patient fears. The research literature supports both.

    Provider factors: Many women with POI are seen by general practitioners or gynecologists without subspecialty training in reproductive endocrinology or menopause medicine. Studies in multiple countries have found that a substantial proportion of providers are unfamiliar with current POI guidelines, underestimate the long-term health risks of untreated POI, or have not updated their prescribing practices since the 2002 WHI publication. Diagnosis itself is often delayed: the average time from first symptom to POI diagnosis has been estimated at 4 to 6 years in some studies, reflecting both the intermittent nature of ovarian function in some cases and the tendency to attribute symptoms to other causes.

    Patient factors: Fear of breast cancer is the dominant barrier on the patient side, a direct legacy of the 2002 WHI coverage. Women who decline HT for POI often cite cancer risk as their primary concern, even though the evidence does not support elevated breast cancer risk from physiological estrogen replacement in a young woman with POI. Addressing this misunderstanding requires time, clear communication, and a provider who is confident explaining why the WHI findings do not apply to a 32-year-old whose ovaries stopped working.

    Fertility concerns can also complicate the HT conversation in a counterproductive way. Some women with POI delay hormone therapy out of concern that it will reduce their already limited chances of spontaneous pregnancy. Current evidence does not support this concern: HT does not suppress the intermittent ovarian activity that underlies spontaneous ovulation in POI, and the cardiovascular and bone protection benefits of starting HT early outweigh theoretical fertility concerns in most cases.

    What Women with POI Should Know

    If you have been diagnosed with POI, or are being evaluated for it, here is what the current evidence supports:

    Hormone therapy is recommended. Every major international guideline recommends HT for women with POI until approximately age 51, unless a specific contraindication exists such as a personal history of hormone-receptor-positive breast cancer or a known high-risk thrombophilia.

    The WHI does not apply to you. The risks identified in that study are not relevant to estrogen replacement in women whose ovaries stopped functioning before age 40. This is worth discussing explicitly with your provider if concern about those findings is part of the conversation.

    The dose may need to be higher than standard HT. Low-dose preparations designed for older postmenopausal women may not restore your estrogen to physiological levels. Ask your provider whether the formulation and dose is appropriate for your age rather than simply the lowest available option.

    Delaying treatment has real consequences. Every year without HT in POI is a year of accelerated bone loss, cardiovascular risk accumulation, and potential neurological effects. The benefits of starting HT early and continuing it to the average age of natural menopause are well established in the guideline literature.

    Seek a provider with POI or reproductive endocrinology experience. Not all gynecologists have current, guideline-concordant knowledge about POI management. The Menopause Society’s practitioner finder can help identify providers with menopause medicine certification. If you are also navigating fertility questions, a reproductive endocrinologist is the appropriate specialist.

    For related women’s health coverage on Health Evidence Digest, see our posts on GLP-1 medications and PCOS fertility research in 2026, new 2026 cervical cancer screening guidelines including self-collection, and the first non-hormonal endometriosis drug entering clinical trials.

    Sources

    Primary study: Use of hormone therapy in patients with premature ovarian insufficiency in tertiary hospitals in Saudi Arabia. Menopause. Published January 21, 2026.

    The Menopause Society press release: Hormone Therapy Underused in Women With Premature Ovarian Insufficiency. menopause.org. January 21, 2026.

    ESHRE POI Guideline: Management of women with premature ovarian insufficiency. European Society of Human Reproduction and Embryology. 2024.

    Menopause Society position statement: The 2023 Menopause Society Position Statement on Hormone Therapy. menopause.org.

    NICE guideline on menopause: Menopause: diagnosis and management. NICE guideline NG23. nice.org.uk.

    POI systematic review and long-term outcomes: Golezar S, et al. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019.

    POI clinical review: Webber L, et al. POI: pathophysiology, presentation, diagnosis, and management. BMJ. 2016.

    Cognitive effects of early menopause: Phung TK, et al. Dementia risk in women with premature ovarian insufficiency and early menopause. PMC9585583.

    WHI overview: Women’s Health Initiative. National Heart, Lung, and Blood Institute.

    NICHD POI resource: Premature Ovarian Insufficiency. nichd.nih.gov.

    Menopause Society practitioner finder: Find a Menopause Healthcare Practitioner. menopause.org.

    Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about hormone therapy for premature ovarian insufficiency should be made in consultation with a qualified healthcare provider who can evaluate individual health history, contraindications, and treatment goals.
  • A Fatal Childhood Disease Has No Treatment. A Gene Therapy with Eight Years of Data Is Now Under FDA Review. Here Is What the Evidence Shows.

    A Fatal Childhood Disease Has No Treatment. A Gene Therapy with Eight Years of Data Is Now Under FDA Review. Here Is What the Evidence Shows.

    📌 The essentials On April 2, 2026, the FDA accepted for review the resubmitted Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy developed by Ultragenyx Pharmaceutical for Sanfilippo syndrome Type A (MPS IIIA). PDUFA date: September 19, 2026. Regulatory history: the FDA previously granted UX111 Priority Review in February 2025. The BLA was originally submitted, received a Complete Response Letter, and was resubmitted in January 2026 with additional long-term clinical data agreed upon with the FDA. The clinical basis: up to 8 years of follow-up showing sustained, significant reductions in CSF heparan sulfate and continued functional improvements compared with natural history, including a 23.2-point Bayley-III cognitive gain (p less than 0.0001) in early-stage patients and median 63.98% CSF heparan sulfate reduction (p less than 0.001). If approved: UX111 would be the first approved therapy for MPS IIIA. There are currently no disease-modifying treatments for this condition. The disease: Sanfilippo syndrome Type A is a rare, fatal lysosomal storage disorder causing progressive neurodegeneration in young children, with a median life expectancy of approximately 15 years.

    Some diseases are called rare because they affect a small number of people. Sanfilippo syndrome is rare in a different sense. It is rare in the way that makes people who learn about it stop mid-sentence. It is a genetic disease that affects young children, causes their nervous systems to progressively deteriorate, and kills most of them in their teenage years. It has no approved treatment.

    Children with Sanfilippo syndrome often appear developmentally normal in early infancy. The first signs, typically behavioral changes and developmental regression, usually emerge between ages 2 and 6, after parents have already formed complete pictures of who their child is. Then the regression accelerates. Language disappears. Motor skills deteriorate. Most children lose the ability to walk, eat independently, and communicate. Median life expectancy is approximately 15 years.

    On April 2, 2026, Ultragenyx Pharmaceutical announced that the FDA has accepted for review its resubmitted Biologics License Application for UX111 (rebisufligene etisparvovec), a one-time intravenous gene therapy for Sanfilippo syndrome Type A. The FDA set a PDUFA action date of September 19, 2026. The clinical data behind this application includes up to eight years of follow-up in treated patients, and the results represent the most robust evidence ever generated for a potential treatment of this disease.

    This post covers what Sanfilippo syndrome Type A is and what it does to the children who have it, how UX111 works, what the clinical trial data actually shows, the regulatory history that preceded this acceptance, and what families and clinicians need to understand about where the program stands.

    What Sanfilippo Syndrome Type A Is

    Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a group of four subtypes (A, B, C, and D) caused by different enzyme deficiencies, all of which result in the accumulation of heparan sulfate, a long-chain sugar molecule, within cells throughout the body. The brain is particularly affected because neurons are especially sensitive to this toxic accumulation.

    Sanfilippo syndrome Type A (MPS IIIA) is the most common and most severe subtype. It is caused by mutations in the SGSH gene, which encodes the enzyme sulfamidase (also called heparan-N-sulfatase). Without functional sulfamidase, heparan sulfate cannot be broken down and accumulates progressively in lysosomes throughout neural and other tissues.

    The disease follows a characteristic three-phase progression:

    Phase 1: Developmental delay or regression, typically appearing between ages 2 and 6. Behavioral symptoms are often prominent, including hyperactivity, aggression, and sleep disturbance. This phase can last several years.

    Phase 2: Severe neurological decline. Language is lost, motor skills deteriorate, and seizures become common. Behavioral symptoms often intensify before this phase.

    Phase 3: Final stage, characterized by profound neurological impairment, loss of ambulation, and complete dependence for all care. Death typically occurs between ages 10 and 20 in most patients, though some survive longer.

    An estimated 3,000 to 5,000 children worldwide have MPS IIIA. In the United States, approximately 1 in 100,000 live births is affected. There are currently no approved disease-modifying treatments in any country.

    The heparan sulfate accumulation problem: why it is so damaging and so hard to treat Heparan sulfate (HS) is a normal component of the extracellular matrix and cell surface in virtually all tissues. The breakdown of heparan sulfate requires a sequential series of enzymes; if any one of them is deficient, partially broken-down HS fragments accumulate in lysosomes. The accumulation is not static: it worsens progressively with age as the substrate burden grows. In the brain, heparan sulfate accumulation triggers inflammatory pathways, impairs autophagy (the cellular waste-disposal process), and causes progressive neuronal death. Because the blood-brain barrier prevents large proteins like enzyme replacements from reaching the central nervous system in therapeutic concentrations, the standard treatment approach for many lysosomal storage disorders, enzyme replacement therapy (ERT), has not been effective for MPS IIIA. ERT can address peripheral manifestations but cannot adequately cross the blood-brain barrier to address the primary site of pathology. This is why gene therapy, which can deliver a functional gene directly into cells that will express the enzyme continuously, is being pursued as the mechanism most likely to address the neurological aspects of the disease.

    How UX111 Works

    UX111 (rebisufligene etisparvovec) is an adeno-associated virus serotype 9 (AAV9) gene therapy. AAV9 is selected for CNS applications because it can cross the blood-brain barrier and transduce neurons efficiently after intravenous administration, which is the critical property that makes it suitable for addressing the neurological pathology in MPS IIIA.

    The therapy delivers a functional copy of the SGSH gene under the control of a promoter designed to drive expression in cells throughout the body, including the central nervous system. Once transduced, cells begin producing functional sulfamidase enzyme, which can then begin breaking down the accumulated heparan sulfate substrate. The enzyme produced in transduced cells can also be taken up by neighboring, non-transduced cells through a process called cross-correction, extending the therapy’s reach beyond the cells directly infected by the viral vector.

    UX111 is administered as a single intravenous infusion. It is not a continuous therapy requiring repeated dosing. The one-time administration is designed to provide durable gene expression over years, which is both the key clinical advantage and one of the central questions the FDA’s review will focus on: how durable is the effect, and for how long?

    The therapy was originally developed by Abeona Therapeutics before being transferred to Ultragenyx, which completed the clinical development program and built out manufacturing capacity. If approved, UX111 will be manufactured entirely within the United States at Andelyn Biosciences in Columbus, Ohio, and at Ultragenyx’s gene therapy manufacturing facility in Bedford, Massachusetts.

    The Clinical Evidence: Eight Years of Follow-Up Data

    The BLA accepted by the FDA on April 2, 2026 is built on a clinical program that has been running since 2015. The primary study is NCT02716246, a Phase 1/2/3 gene transfer clinical trial conducted across multiple sites.

    The data package includes two categories of evidence that together form the basis for the accelerated approval application: biomarker data (cerebrospinal fluid heparan sulfate levels) and functional clinical data across multiple developmental domains.

    Biomarker evidence: CSF heparan sulfate reduction

    Cerebrospinal fluid heparan sulfate (CSF-HS) is the primary biomarker for MPS IIIA disease activity. Elevated CSF-HS directly reflects the accumulation of toxic substrate in the CNS. Sustained reduction of CSF-HS is the proposed intermediate clinical endpoint for the accelerated approval, as agreed with the FDA during the prior clinical review.

    Across the trial cohort, UX111 produced a median reduction of approximately 63.98% in CSF-HS levels (p less than 0.001) over a median follow-up of approximately 4.8 years. An earlier data analysis using time-normalized area under the curve (AUC) methodology to capture cumulative substrate reduction across the full follow-up period found a mean reduction of 63% (p less than 0.0001). The reductions were sustained and not limited to early post-treatment timepoints, supporting the durability of the gene expression.

    Functional clinical data: separation from natural history

    Because MPS IIIA is a progressive disease with a well-characterized natural history trajectory, treated patients can be compared to what the expected course of the disease would be without intervention. This natural history comparison is the primary method for evaluating functional benefit in the absence of a randomized placebo-controlled trial, which is not ethically feasible in a fatal pediatric disease.

    Outcome measureFindingStatistical significance
    Bayley-III cognitive composite (early-stage patients)+23.2-point gain versus natural historyp less than 0.0001
    Communication skills retentionMaintained beyond ages when untreated peers typically lose languageSignificant separation from natural history
    AmbulationContinued walking beyond expected loss age in many treated patientsSignificant separation from natural history
    Self-feedingRetained in treated patients beyond typical loss age in untreated peersSignificant separation from natural history
    CSF heparan sulfate reductionMedian 63.98% reductionp less than 0.001
    Follow-up durationUp to 8 years; median approximately 4.8 yearsLongest follow-up in any MPS IIIA therapeutic program

    Source: Ultragenyx press release February 3, 2026. WORLDSymposium 2026 presentation. NCT02716246.

    The 23.2-point Bayley-III cognitive gain in early-stage patients is the most clinically striking number in the dataset. The Bayley Scales of Infant and Toddler Development (Bayley-III) is a standardized developmental assessment. A 23-point gain against a natural history trajectory that is declining represents the children treated with UX111 not just slowing their decline but functioning meaningfully better than where their disease would have taken them without treatment.

    The consistency of the results across age groups and disease severity levels at enrollment is also significant. Children who were treated at earlier stages of disease showed the largest functional gains, which is consistent with the biology: gene therapy that reduces substrate accumulation is more effective when there is less existing neuronal damage to overcome. But even children treated at more advanced disease stages showed meaningful separation from natural history in terms of skill retention.

    Ultragenyx’s Chief Scientific Officer characterized the data at the time of the BLA resubmission as demonstrating “a remarkable and unprecedented separation from the natural history of Sanfilippo syndrome through more than eight years of follow-up, with children in their teens retaining skills at an age when many of their untreated peers have sadly lost them.”

    The Regulatory History: Why This Is a Resubmission

    Understanding why this is a resubmitted BLA rather than an initial submission requires knowing what happened the first time.

    Ultragenyx originally submitted the UX111 BLA to the FDA and received a Complete Response Letter, meaning the FDA determined the application was not approvable as submitted and identified deficiencies that needed to be addressed before approval could be considered.

    The specific deficiencies cited in the CRL centered on the evidentiary standard for the intermediate clinical endpoint supporting accelerated approval. The FDA’s position was that additional long-term clinical data on neurological function would be needed to support the proposed surrogate endpoint of CSF-HS reduction as reasonably likely to predict clinical benefit. Ultragenyx and the FDA agreed during subsequent discussions on what additional data would be required, and the company continued following patients and collecting data.

    The resubmission in January 2026, accepted on April 2, 2026, includes those agreed-upon longer-term data. The FDA’s acceptance with a PDUFA date confirms that the agency considers the resubmission complete and the identified deficiencies addressed. It does not guarantee approval but indicates that the evidentiary package meets the threshold for full review.

    The FDA granted the UX111 BLA Priority Review in February 2025, which compresses the review timeline from the standard 12 months to 6 months. The September 19, 2026 PDUFA date reflects Priority Review timing from the January 2026 resubmission.

    What accelerated approval means for UX111 Accelerated approval is an FDA pathway that allows approval of drugs for serious conditions based on a surrogate or intermediate clinical endpoint that is reasonably likely to predict clinical benefit, rather than requiring demonstration of direct clinical benefit in pivotal trials. For UX111, the proposed surrogate endpoint is CSF heparan sulfate reduction, which is biologically linked to the neurological pathology: less HS accumulation in the CNS should translate to less neuronal damage and better preservation of function. The additional clinical data in the resubmission, showing functional gains on Bayley-III and other measures alongside the CSF-HS reductions, provides supporting evidence that the surrogate is tracking real neurological benefit. If UX111 receives accelerated approval, continued approval would be contingent on verification of clinical benefit in a confirmatory trial. This is the standard condition of accelerated approval across all indications. For a disease as rare as MPS IIIA, designing and executing a confirmatory trial after approval raises its own logistical questions that the field will need to navigate.

    Regulatory Designations and Their Significance

    UX111 holds multiple regulatory designations in the United States and Europe, each reflecting a different aspect of its development program:

    DesignationGrantorWhat it means
    Priority ReviewFDA (February 2025)Compresses review timeline to 6 months from standard 12
    Regenerative Medicine Advanced Therapy (RMAT)FDAIntensive FDA guidance and interaction; eligibility for accelerated approval, priority review, rolling review
    Fast TrackFDAMore frequent FDA meetings; rolling review eligibility
    Rare Pediatric DiseaseFDAEligible for priority review voucher upon approval
    Orphan DrugFDA7 years market exclusivity; tax credits for clinical development
    PRIME designationEMAEnhanced early dialogue and guidance for promising medicines
    Orphan Medicinal ProductEMAEuropean market exclusivity for 10 years

    The Rare Pediatric Disease designation is worth specific attention. If UX111 is approved under this designation, Ultragenyx would receive a Priority Review Voucher (PRV) that can be used by the company or sold to another pharmaceutical company to accelerate a different drug’s FDA review. These vouchers have sold for hundreds of millions of dollars and represent a significant financial incentive structure that Congress created specifically to encourage development of therapies for rare pediatric diseases.

    Safety: What the Clinical Program Shows

    Across the clinical trials with follow-up of up to 8 years, UX111 has maintained what Ultragenyx describes as an acceptable and favorable safety profile. No unexpected or serious safety signals have been identified in the long-term follow-up data.

    The general safety considerations for AAV9 gene therapy apply to UX111:

    Immune responses: AAV capsid can trigger immune responses. Patients with pre-existing immunity to AAV9 (neutralizing antibodies) are typically screened and may be ineligible for treatment. The immune response to the viral vector is a key safety monitoring point in the weeks immediately following infusion.

    Liver enzyme elevations: Transient elevations in liver enzymes are a known effect of AAV gene therapies, reflecting immune-mediated responses to transduced hepatocytes. Corticosteroid prophylaxis is used to manage these responses and has been incorporated into the treatment protocol.

    Long-term gene expression: While durable expression is the goal, the long-term behavior of AAV9 in pediatric patients who are still growing and developing is an area of ongoing monitoring. The 8-year follow-up data is reassuring on this point but continued surveillance is appropriate.

    Genotoxicity: Insertional mutagenesis from AAV vectors is considered low-risk compared to integrating viral vectors, but it is not zero, and long-term registry follow-up is standard practice for gene therapy recipients.

    The full prescribing information, when and if it is issued, will contain the complete safety profile from the clinical program.

    What This Means for Families Affected by MPS IIIA

    If your child has been diagnosed with Sanfilippo syndrome Type A, or you are supporting a family navigating this diagnosis, here is what the September 19, 2026 PDUFA date means and does not mean:

    BLA acceptance is not approval. The FDA has accepted the application for review and set a decision target date. The agency will conduct its own independent analysis of all submitted data. The outcome could be approval, a request for additional information, or another Complete Response Letter.

    The PDUFA date is a target, not a guarantee. Decisions can come on or before the PDUFA date. The FDA could also extend the review if it identifies issues requiring additional analysis.

    Earlier treatment appears to produce better outcomes. The clinical data consistently shows that children treated at earlier disease stages had larger functional gains. If UX111 is approved, treatment timing relative to disease stage will likely be a central clinical consideration.

    No treatment is currently approved. While the BLA is under review, MPS IIIA remains without any disease-modifying approved therapy. Families should continue working with metabolic disease specialists at centers with lysosomal storage disorder expertise.

    Clinical trial participation remains available. NCT02716246 continues to follow existing participants. Families interested in clinical trial options can search ClinicalTrials.gov for currently enrolling studies.

    The most current patient-facing resources are maintained by the National MPS Society, which provides disease information, family support, and physician referral guidance. The NORD rare disease database also maintains a current overview of MPS IIIA. The NIH Genetic and Rare Diseases Information Center provides clinical and research information including ongoing trial listings.

    For context on how the FDA has approached other gene therapy approvals for rare pediatric diseases, including the recent approval of the first gene therapy for genetic deafness, see our post on Otarmeni and what the first gene therapy approval under the CNPV program means for the field.

    Sources

    FDA BLA acceptance press release: Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA). GlobeNewswire. April 2, 2026.

    BLA resubmission press release: Ultragenyx Resubmits Biologics License Application for UX111. Ultragenyx IR. January 30, 2026.

    Long-term clinical data press release: Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS. GlobeNewswire. February 3, 2026.

    CSF-HS correlation data: Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid. Ultragenyx IR.

    Clinical trial registration: NCT02716246. Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.HsGSH for MPS IIIA. ClinicalTrials.gov.

    MPS IIIA disease overview: Mucopolysaccharidosis Type IIIA. StatPearls. NCBI.

    Heparan sulfate and MPS IIIA biology: Heparan Sulfate Proteoglycans in Neurodegeneration. PMC5026768.

    NIH GARD MPS IIIA: Mucopolysaccharidosis type IIIA. rarediseases.info.nih.gov.

    Accelerated approval pathway: Accelerated Approval. FDA.gov.

    RMAT designation: Regenerative Medicine Advanced Therapy Designation. FDA.gov.

    Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

    Bayley-III assessment: Bayley Scales of Infant and Toddler Development. PMC6052512.

    ERT limitations in MPS: Enzyme Replacement Therapy for Lysosomal Storage Disorders. PMC5814258.

    Patient resources: National MPS Society | NORD: MPS III | NIH GARD | ClinicalTrials.gov: MPS IIIA

    Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. UX111 (rebisufligene etisparvovec) is not yet FDA-approved. Families navigating a Sanfilippo syndrome Type A diagnosis should work with a metabolic disease specialist at a center with lysosomal storage disorder expertise.
  • Younger Endometrial Cancer Survivors Face Years of Unnecessary Suffering. New Evidence Says One Treatment Has Been Wrongly Withheld.

    Younger Endometrial Cancer Survivors Face Years of Unnecessary Suffering. New Evidence Says One Treatment Has Been Wrongly Withheld.

    📌 The essentials A study published in Menopause, the journal of The Menopause Society, on March 4, 2026 analyzed data from more than 2,800 women aged 18 to 51 with endometrial cancer across 68 U.S. healthcare organizations. The key finding: local, low-dose vaginal estrogen therapy was not associated with elevated risk of endometrial cancer recurrence compared to women who did not use it. Only 5.6% of eligible women in the dataset had initiated vaginal estrogen therapy, despite its documented benefits for genitourinary symptoms of menopause. This is the largest known U.S. study to examine this specific question. The study population: women aged 18 to 51, meaning younger survivors experiencing treatment-induced early menopause. Mean treatment duration in the vaginal ET group: 1.88 years. Important context: the FDA removed the boxed warning from low-dose vaginal estrogen products in 2023, a regulatory change that preceded this study and that this data now supports clinically.

    There is a specific kind of suffering that is common enough to have a clinical name but uncommon enough that it tends to fall through the cracks of oncology care. Women who survive endometrial cancer at younger ages, typically through hysterectomy that removes both ovaries, experience sudden, complete estrogen loss. Not the gradual perimenopausal transition that most women navigate. Abrupt menopause, overnight, in their 30s or 40s.

    The symptoms can be severe. Genitourinary syndrome of menopause (GSM), the clinical term for the collection of vaginal, vulvar, and urinary symptoms caused by estrogen deficiency, does not improve on its own. Vaginal tissue atrophies. Intercourse becomes painful or impossible. Urinary urgency, frequency, and recurrent infections become chronic. Hot flashes disrupt sleep. And the women dealing with all of this are often told they cannot use estrogen because they have had a hormone-sensitive cancer.

    A study published in Menopause on March 4, 2026 is the largest U.S. analysis to date addressing whether that restriction is justified for low-dose vaginal estrogen specifically. The finding is reassuring: among younger survivors of endometrial cancer who used local, low-dose vaginal estrogen therapy, the risk of cancer recurrence was not elevated compared to survivors who did not use it.

    Endometrial Cancer in Younger Women: The Problem This Study Is Addressing

    Endometrial cancer is the most common gynecologic malignancy in the United States, with approximately 67,000 new diagnoses annually. It is predominantly a postmenopausal disease, but incidence in younger women has been rising steadily. The press release accompanying this study cited an increase in early-onset endometrial cancer from 2.2 to 3.3 per 100,000 women in those aged 50 and younger between 2000 and 2019 in the United States. That is a 50% increase in incidence over two decades in a population that was previously considered relatively low-risk.

    The reasons for the increase are not fully established, but the association with obesity and metabolic syndrome is well documented. Excess adipose tissue converts androgen precursors to estrone, producing chronically elevated estrogen levels without the counterbalancing effect of progesterone, which is the endometrial carcinogen driving most endometrioid-type endometrial cancers.

    Most early-stage endometrial cancers are treated with hysterectomy, often including bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes). For premenopausal women, oophorectomy causes immediate surgical menopause. Some patients also receive radiation therapy or chemotherapy, which can further damage ovarian function and exacerbate menopausal symptoms.

    The result is that a woman who is 38, or 44, or 50, who has just finished cancer treatment and is in remission, may be experiencing menopausal symptoms that are more severe than what most women in natural menopause experience, with fewer treatment options available because of the cancer history.

    Why Vaginal Estrogen Has Been Avoided — and Why That May Be Changing

    The reluctance to prescribe estrogen of any kind to endometrial cancer survivors is rooted in a legitimate biological concern. Most endometrial cancers are estrogen-receptor positive, meaning estrogen exposure is implicated in their development. The standard thinking has been that restoring any estrogen after treatment might stimulate residual or occult cancer cells.

    That concern has been compounded for years by labeling: until 2023, all estrogen-containing products, including low-dose vaginal formulations, carried an FDA boxed warning stating risks that were established from studies of systemic, higher-dose hormonal therapy. The warning did not differentiate between oral estrogen pills taken systemically and a small estradiol tablet inserted vaginally, even though the pharmacokinetics are fundamentally different.

    Low-dose vaginal estrogen products work locally. A vaginal estradiol tablet or ring at the lowest available doses produces serum estradiol levels that remain within the normal postmenopausal range, because the product is absorbed primarily through vaginal tissue to act locally, with minimal systemic absorption. This is pharmacologically distinct from swallowing an estrogen pill that circulates throughout the body.

    In 2023, the FDA recognized this distinction and removed the boxed warning from low-dose vaginal estrogen products, updating their labeling to reflect that the systemic exposure and associated risks documented for systemic hormone therapy do not apply to these preparations. The clinical study published in March 2026 now provides real-world evidence supporting that regulatory decision specifically in the context of endometrial cancer survivors.

    The Study: Design, Population, and Results

    The study, published in the March 2026 issue of Menopause, drew on electronic health records and insurance claims data from 68 healthcare organizations across the United States. Researchers identified women aged 18 to 51 who had been diagnosed with endometrial cancer.

    From that dataset of more than 2,800 women, they created a matched cohort design: 1,412 survivors who had initiated local, low-dose vaginal estrogen therapy were matched 1:1 with 1,412 survivors who had not used it. The matching approach controls for confounding by ensuring the two groups were comparable in relevant baseline characteristics.

    The mean duration of vaginal ET use in the treatment group was 1.88 years. This is important context that the original stub post did not provide: nearly two years of use, not a brief test course. That duration makes the non-elevated recurrence finding more clinically meaningful, because it addresses the question of sustained exposure rather than just initial use.

    Primary findingVaginal ET use was not associated with elevated risk of endometrial cancer recurrence compared to matched non-users
    Matched cohort size1,412 ET users matched 1:1 with 1,412 non-users
    Overall study populationMore than 2,800 women aged 18 to 51 with endometrial cancer across 68 U.S. healthcare organizations
    Mean treatment duration1.88 years
    Vaginal ET initiation rateOnly 5.6% of eligible younger survivors
    Study scopeLargest known U.S. analysis of endometrial cancer recurrence with local, low-dose vaginal ET in this population

    Source: Vaginal estrogen therapy utilization and associated outcomes in younger survivors of endometrial cancer. Menopause. March 4, 2026.

    The 5.6% initiation rate is the second major finding and arguably the more actionable one. If only about 1 in 18 eligible younger survivors is using a therapy that the evidence now suggests is safe and that addresses symptoms the press release describes as rarely improving without treatment, there is a large gap between what the data supports and what is happening in clinical practice.

    What the Study Does and Doesn’t Tell Us

    The finding is reassuring, but several limitations are worth understanding before interpreting it as a definitive clearance for vaginal estrogen in all endometrial cancer survivors.

    Study design limitations: This is a retrospective cohort study using electronic health records and insurance claims data, not a randomized controlled trial. Matched cohort designs control for measured confounders, but unmeasured confounding is always possible. Women who received vaginal ET may have had systematically different disease characteristics, follow-up patterns, or oncologist preferences than those who did not, even after matching.

    Short-term follow-up: A mean treatment duration of 1.88 years is meaningful but may not capture recurrence events that occur at later timepoints. Endometrial cancer recurrence can happen years after treatment, and longer-term follow-up data from this population would be valuable.

    Histologic heterogeneity: Endometrial cancers are not all the same. Endometrioid adenocarcinoma (Type I), the most common subtype, is strongly estrogen-driven. Type II tumors, including serous, clear cell, and carcinosarcoma, are not estrogen-driven in the same way and carry a worse prognosis. The press release does not report subtype-specific recurrence rates, and understanding whether the safety finding holds equally across all subtypes matters for individual patient counseling.

    Stage distribution: Similarly, the study’s population spans early and potentially more advanced stages. Whether the non-elevated recurrence finding holds for women with higher-stage disease at diagnosis is not fully reported in the press release summary.

    These limitations do not undermine the study’s value. They are the normal caveats that attend any real-world evidence study in a rare clinical situation where a randomized trial is not feasible. The appropriate interpretation is that the largest available U.S. evidence base is reassuring, not that the question is fully settled.

    How vaginal estrogen is different from systemic hormone therapy: the pharmacokinetics that matter Systemic hormone therapy, whether oral tablets, transdermal patches, or injectable formulations, is absorbed into the bloodstream and distributes estrogen throughout the body. This systemic exposure is what drives the risks of blood clots, breast cancer, and cardiovascular events documented in studies like the Women’s Health Initiative. Low-dose vaginal estrogen works differently. Products such as low-dose vaginal estradiol tablets (e.g., Vagifem), estradiol vaginal rings at the lowest dose (Estring), and vaginal cream at low doses act primarily on the local vaginal tissue. Studies measuring serum estradiol levels in postmenopausal women using these products have found that systemic absorption is minimal, with levels remaining in the normal postmenopausal range rather than rising to premenopausal levels. This pharmacokinetic difference is the basis for the FDA’s 2023 decision to remove the systemic HT boxed warning from these products, and it is the biological rationale for why vaginal estrogen may be safer in cancer survivors than systemic formulations.

    What This Means for Younger Survivors of Endometrial Cancer

    Genitourinary syndrome of menopause (GSM) includes vaginal dryness, vaginal atrophy, pain during intercourse (dyspareunia), urinary urgency, frequency, and recurrent urinary tract infections. It is one of the most bothersome and least discussed consequences of cancer treatment in younger women, and unlike hot flashes, which tend to diminish over time for many women, GSM does not improve without treatment. It often worsens.

    The nonhormone options for GSM, including vaginal moisturizers, lubricants, and in some cases ospemifene (an oral selective estrogen receptor modulator for dyspareunia), provide partial relief for some women but not the tissue restoration that estrogen produces. Laser and radiofrequency-based treatments for vaginal atrophy are also available but lack the long-term evidence base of vaginal estrogen.

    Dr. Monica Christmas, associate medical director for The Menopause Society, noted in the study commentary that genitourinary symptoms associated with menopause rarely improve without treatment and are exacerbated in the context of abrupt, early menopause. She emphasized that helping survivors of endometrial cancer make evidence-based decisions about their care is empowering, especially during a vulnerable time, and that expanding treatment options to include local, low-dose vaginal estrogen will have long-lasting benefits for this population.

    If you are a younger survivor of endometrial cancer experiencing genitourinary symptoms, here is what the current evidence supports:

    Vaginal estrogen has now been studied in this specific population. This is no longer an area with no data. The largest U.S. study to examine this question found no elevated recurrence risk with mean nearly two-year use.

    The conversation with your oncologist is evidence-based now. If you have been told vaginal estrogen is off-limits because of your cancer history, this study is directly relevant to that conversation. The appropriate clinical decision involves your specific cancer type, stage, time since treatment, and current health status, but the blanket restriction is increasingly unsupported by the available evidence.

    The FDA removed the boxed warning in 2023. This regulatory change means low-dose vaginal estrogen no longer carries the same warning label as systemic hormone therapy. Your pharmacist or prescriber may not have updated you on this.

    Initiation rates are low, but they should not be. Only 5.6% of eligible younger survivors in this large dataset had used vaginal estrogen. That number is likely a reflection of the fear and misinformation that this and future studies are meant to address.

    What to ask your care team: Whether local, low-dose vaginal estrogen is appropriate for your specific cancer type and stage; which formulation (tablet, ring, or cream) is appropriate; what monitoring is reasonable during use; and whether referral to a gynecologic oncologist or menopause specialist is indicated for this conversation.

    The Menopause Society’s practitioner finder can help locate clinicians with menopause medicine certification who are familiar with hormone therapy decisions in cancer survivors. The Society of Gynecologic Oncology is the primary professional organization for gynecologic cancer specialists and maintains patient resources on endometrial cancer survivorship.

    This study is part of a broader shift in women’s health toward evidence-based approaches that address the full consequences of cancer treatment rather than simply managing the tumor. For related coverage, see our posts on the first approved immunotherapy for ovarian cancer, hormone therapy underuse in women with premature ovarian insufficiency, and the first non-hormonal endometriosis drug entering human trials.

    Sources

    Primary study: Vaginal estrogen therapy utilization and associated outcomes in younger survivors of endometrial cancer. Menopause. March 4, 2026.

    The Menopause Society press release: Vaginal Estrogen Therapy Not Linked to Cancer Recurrence in Survivors of Endometrial Cancer. menopause.org. March 4, 2026.

    FDA boxed warning removal: FDA Removes Boxed Warning from Low-Dose Vaginal Estrogen Products. FDA.gov. 2023.

    Endometrial cancer overview: Uterine Cancer. National Cancer Institute.

    Endometrial cancer and estrogen receptor biology: Endometrial Cancer: Molecular Subtypes and Hormonal Sensitivity. PMC7698737.

    Genitourinary syndrome of menopause: Genitourinary Syndrome of Menopause: An Overview of Clinical Manifestations, Pathophysiology, Etiology, Evaluation, and Management. PMC7349626.

    ACOG hysterectomy resource: Hysterectomy: FAQs. American College of Obstetricians and Gynecologists.

    Obesity and endometrial cancer: Obesity and Cancer. National Cancer Institute.

    Metabolic syndrome overview: Metabolic Syndrome. StatPearls. NCBI.

    Ospemifene FDA approval: FDA approves ospemifene for vaginal dryness and pain during sex due to menopause. FDA.gov.

    Menopause Society practitioner finder: Find a Menopause Healthcare Practitioner.

    Patient resources: The Menopause Society | Society of Gynecologic Oncology | American Cancer Society: Endometrial Cancer | National Cancer Institute: Uterine Cancer

    Disclaimer: Health Evidence Digest provides general information about health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about hormone therapy use in endometrial cancer survivors should be made in consultation with a gynecologic oncologist and/or a clinician experienced in menopause medicine, taking into account individual cancer type, stage, treatment history, and current health status.
  • The FDA Just Removed the Age Limit on Needle-Free Epinephrine. Here Is What Families and Caregivers Need to Know.

    The FDA Just Removed the Age Limit on Needle-Free Epinephrine. Here Is What Families and Caregivers Need to Know.

    📌 The essentials On March 27, 2026, the FDA approved a label update for neffy 1 mg (epinephrine nasal spray, ARS Pharmaceuticals) removing the minimum age requirement from the indication. Any patient weighing 33 pounds (15 kg) or more can now use neffy 1 mg for emergency treatment of Type I allergic reactions, including anaphylaxis, regardless of age. Previously, the 1 mg dose required patients to be at least 4 years old AND weigh between 33 and 66 pounds. The age floor is now gone entirely. Who this affects: approximately 25% of patients in the 33 to 66 pound weight range are under age 4, a group that was previously excluded despite meeting the weight criterion and facing real anaphylaxis risk. The label update also clarified: sniffing after administration is not required for the drug to work; the device remains usable if accidentally frozen and thawed; high-temperature exposure up to 122°F for brief periods does not compromise the product. What neffy is: a needle-free intranasal epinephrine spray that delivers epinephrine through the nasal mucosa without injection, cleared as the first non-injectable epinephrine option for anaphylaxis. Available in two doses: neffy 1 mg for patients 33 to 66 pounds (15 to 30 kg) and neffy 2 mg for patients 66 pounds or more (30 kg or more).

    Anaphylaxis is a medical emergency. It can progress from first symptoms to respiratory failure or cardiovascular collapse within minutes. The only FDA-approved first-line treatment is epinephrine, and the evidence is unambiguous: early administration saves lives. Delayed administration of epinephrine is a consistent factor in anaphylaxis fatalities.

    Yet epinephrine is frequently not given when it should be, and the reason is often not the absence of a device. It is fear of the needle.

    Multiple studies have documented that a significant proportion of caregivers, parents, and even patients delay or avoid using epinephrine autoinjectors because of needle phobia, fear of injuring the child or themselves during a high-stress emergency, or hesitation about whether the situation truly warrants injection. One survey found that fewer than half of patients at risk for anaphylaxis consistently carry their epinephrine, and non-adherence is frequently attributed to the injection format itself.

    neffy (epinephrine nasal spray) was developed specifically to address this barrier. It delivers epinephrine through the nasal mucosa without a needle. It is compact, discreet, and does not require injection technique. The March 27, 2026 label update makes it accessible to the youngest weight-eligible patients for the first time.

    What Changed and Why It Matters

    The original neffy 1 mg approval in May 2025 included a pediatric age restriction: patients using the 1 mg dose had to be at least 4 years old in addition to meeting the 33 to 66 pound weight criterion. Children under 4 who were in the eligible weight range were excluded from the labeled indication.

    The updated label removes the age floor entirely. Eligibility is now determined solely by weight: 33 pounds or more for the 1 mg dose, regardless of how old the patient is.

    This is not a small gap. Approximately 25% of patients in the 33 to 66 pound weight range are under 4 years of age. Anaphylaxis in young children is not rare. Food allergies affect approximately 8% of children, and the foods most commonly causing severe reactions in young children, including peanuts, tree nuts, milk, and egg, are foods that toddlers and preschool-aged children routinely encounter. A 3-year-old who weighs 35 pounds and has a severe peanut allergy was previously outside the labeled indication for neffy despite being in the labeled weight range. That gap is now closed.

    The Clinical Evidence Behind the Label Expansion

    The age requirement was removed based on clinical data presented to the FDA, including pharmacokinetic and pharmacodynamic evidence. Here is what the data shows.

    Pharmacokinetic equivalence to injectable epinephrine

    The original approval of neffy 1 mg was based on extensive clinical trials demonstrating that pharmacokinetic and pharmacodynamic responses in pediatric and adult subjects were consistent with those of injectable epinephrine products. This means neffy delivers comparable blood concentrations of epinephrine and produces comparable effects on blood pressure and heart rate as intramuscular autoinjector products.

    This is the pharmacological foundation of the entire neffy program: if the blood epinephrine levels achieved are equivalent, the clinical effect should be equivalent. That equivalence was established in healthy adults and pediatric subjects in the original approval.

    Real-world effectiveness data

    Since neffy’s approval, real-world prescribing data has been accumulating. Real-world data show that a single dose of neffy achieves an 89.2% symptom resolution rate in anaphylaxis, comparable to the 88.9% rate observed with intramuscular epinephrine autoinjectors. That near-identical real-world effectiveness rate across the two delivery formats is a meaningful data point for families deciding between options.

    Pediatric trial response data

    In pediatric clinical trials, 100% of patients responded to a single dose of neffy, with a median response time of 16 minutes. Adverse events in pediatric trials were generally mild and transient, consistent with the known epinephrine side effect profile (increased heart rate, pallor, tremor) rather than drug-specific adverse effects from the nasal route.

    Human factors studies

    Human factors studies demonstrated that children as young as 10 years old can use neffy effectively by following the instructions, and that untrained individuals, including babysitters, teachers, and other non-medical caregivers, can successfully administer the device in simulated emergency conditions. This real-world usability finding is as important as the pharmacokinetic data for a rescue medication whose effectiveness depends on whether it actually gets used.

    The Other Label Updates: Storage and Administration Clarifications

    The March 27 label update also includes several practical clarifications that address common questions and concerns caregivers have raised:

    What changedWhat it means in practice
    Sniffing after administration is not requiredPreviously unclear whether patients needed to sniff to pull the medication deeper into the nasal cavity. The label now clarifies that normal administration is effective regardless of whether the patient sniffs. This matters for small children who may not follow instructions during an allergic emergency.
    Accidental freezing does not render the device unusableIf neffy is accidentally frozen and thawed, it can still be used. Previously, accidental freezing was a concern that might lead caregivers to discard the device.
    High temperature excursions up to 122°F permittedBrief exposure to temperatures as high as 122°F (50°C) does not compromise product quality. This matters for devices stored in car glove compartments, diaper bags, or outdoor settings in warm climates.
    Carrying case included with each prescription cartonBeginning this summer, each carton will include a carrying case. Availability is intended to improve day-to-day portability and reduce the barrier to carrying the device consistently.

    How neffy Compares to Other Epinephrine Options

    Epinephrine remains the only FDA-approved medication for anaphylaxis. It is not optional or a second-line measure: antihistamines like diphenhydramine (Benadryl) do not treat anaphylaxis and are not substitutes. For any patient at risk for anaphylaxis, carrying epinephrine is the medical standard.

    The available options in the U.S. currently include:

    ProductFormatDoses availableWeight-based dosingAge restriction
    EpiPen / EpiPen JrIntramuscular autoinjector (spring-loaded, needle-based)0.3 mg (adult), 0.15 mg (Jr)0.15 mg for 33 to 66 lbs; 0.3 mg for 66 lbs or moreNo age floor, weight-based
    Auvi-QIntramuscular autoinjector (needle-retractable, with voice instructions)0.1 mg, 0.15 mg, 0.3 mgMultiple doses for different weight ranges including 16 to 33 lbsNo age floor, weight-based
    neffy 1 mgIntranasal spray, no needle1 mgFor patients 33 to 66 lbs (15 to 30 kg)No age floor as of March 27, 2026
    neffy 2 mgIntranasal spray, no needle2 mgFor patients 66 lbs or more (30 kg or more)No age floor

    The key practical difference is the delivery mechanism. EpiPen and Auvi-Q are effective, extensively studied intramuscular products with long track records. Auvi-Q’s voice instructions and needle-retraction design address some of the usability concerns associated with EpiPen, but both still require needle injection. neffy’s non-injectable format does not replace injection-based options but adds a choice for patients, families, and caregivers for whom needle administration is a real barrier.

    Clinically, the two approaches should be considered equivalent in terms of epinephrine delivery based on the pharmacokinetic data. The choice between them is appropriately individualized based on patient preference, caregiver confidence, and clinical judgment.

    The anaphylaxis delay problem: why needle hesitancy has clinical consequences Delayed epinephrine administration is the most common preventable factor in anaphylaxis fatalities. Studies consistently show that patients, parents, and bystanders delay using epinephrine for multiple reasons: uncertainty about whether symptoms are severe enough, concern about hurting the patient with a needle, fear of accidentally self-injecting, and lack of confidence in administering a needle device under pressure. Each minute of delay in epinephrine administration during a severe anaphylactic reaction increases the risk of cardiovascular and respiratory compromise. Antihistamines, commonly given as a first response, do not block the systemic cascade that makes anaphylaxis life-threatening. They treat urticaria (hives) and mild symptoms but cannot prevent or reverse anaphylactic shock. The clinical rationale for neffy is not that intranasal epinephrine is pharmacologically superior to injected epinephrine. The rationale is that a treatment which is equivalent in pharmacokinetics but significantly more likely to be used promptly by hesitant caregivers is clinically superior in practice, even if it is equivalent in theory.

    Dosing, Administration, and What Caregivers Need to Know

    Weight-based dosing is the rule:

    • neffy 1 mg: patients weighing 33 to 66 pounds (15 to 30 kg), any age
    • neffy 2 mg: patients weighing 66 pounds or more (30 kg or more), any age

    Administration:

    1. Remove the device from the case.
    2. Hold the device upright with your thumb on the bottom and two fingers on the nozzle.
    3. Insert the nozzle into one nostril. The patient does not need to sniff.
    4. Press firmly to release the dose.
    5. If symptoms do not improve within 5 minutes or worsen, administer a second dose in the same nostril from a second device.
    6. Call 911 or go to the nearest emergency room immediately after use, even if symptoms improve.

    Carry two devices: Current prescribing guidelines recommend carrying two epinephrine devices at all times because biphasic anaphylaxis, where symptoms return after initial improvement, can occur in approximately 1 in 5 anaphylaxis events.

    Storage guidance: neffy can be stored at room temperature. Brief exposure up to 122°F is permitted. If accidentally frozen, it can be thawed and used. Keep the cap on between uses. The shelf life is 24 months at room temperature.

    When to call 911: Always. Even after epinephrine administration and apparent symptom improvement, anaphylaxis requires emergency medical evaluation because of biphasic reaction risk.

    What This Means for Schools, Daycares, and Emergency Preparedness

    The removal of the age restriction has implications beyond individual families. Schools and daycare facilities with anaphylaxis emergency plans now have an additional option to consider for their youngest students who meet weight criteria. Many early childhood programs struggle with the needle administration training requirements that injectable epinephrine demands of staff, and untrained-user data showing effective neffy administration by non-medical personnel is directly relevant in these settings.

    FARE (Food Allergy Research and Education) maintains resources for schools navigating food allergy emergency planning. ACAAI (American College of Allergy, Asthma and Immunology) provides clinical guidance on anaphylaxis preparedness. Both organizations’ resources may be updated to reflect the age restriction removal.

    Sources

    ARS Pharmaceuticals press release (March 27, 2026): ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label. GlobeNewswire.

    ARS Pharmaceuticals IR page: ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement. ir.ars-pharma.com.

    Original neffy 1 mg approval (May 2025): ARS Pharmaceuticals Announces FDA Approval of neffy 1 mg. ir.ars-pharma.com.

    FDA drug approval page: FDA approves epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. FDA.gov.

    Pharmacy Times coverage: FDA Removes Age Restriction for neffy 1 mg, Expanding Access to Needle-Free Epinephrine. pharmacytimes.com. March 2026.

    Contemporary Pediatrics coverage (with 89.2% real-world data): FDA removes age restriction for epinephrine nasal spray. contemporarypediatrics.com. March 2026.

    Epinephrine delay and anaphylaxis fatalities: Epinephrine Use and Barriers to Carrying. PMC6290645.

    Anaphylaxis overview: AAAAI Anaphylaxis.

    Food allergy statistics: Facts and Statistics. FARE.

    Patient and caregiver resources: FARE: Food Allergy Research and Education | ACAAI Anaphylaxis | AAAAI Anaphylaxis | neffy prescribing information

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Patients with known or suspected anaphylaxis risk should work with a board-certified allergist or immunologist to establish an individualized emergency action plan. Always call 911 after epinephrine administration, even if symptoms appear to resolve.
  • An Experimental Immunotherapy Just Got FDA Orphan Drug Status for Sarcoma. Here Is What the EFTISARC-NEO Trial Data Actually Shows.

    An Experimental Immunotherapy Just Got FDA Orphan Drug Status for Sarcoma. Here Is What the EFTISARC-NEO Trial Data Actually Shows.

    📌 The essentials On April 15, 2026, the FDA granted Orphan Drug Designation to eftilagimod alfa (IMP321, Immutep) for the treatment of soft tissue sarcoma. The designation is based on data from the Phase 2 EFTISARC-NEO trial (NCT06128863), which met its primary endpoint with a median tumor hyalinization and fibrosis of 51.5% across 38 evaluable patients, well above both the trial’s prespecified threshold of 35% and the historical benchmark of approximately 15% with radiotherapy alone. What eftilagimod alfa is: a soluble form of LAG-3 protein that activates antigen-presenting cells to stimulate a broad immune response. It is not a checkpoint inhibitor. It works through a distinct, complementary mechanism to pembrolizumab. What Orphan Drug Designation means: eligibility for 7 years of market exclusivity, tax credits for clinical development costs, fee waivers, and enhanced FDA guidance. It does not mean the drug is approved or that approval is certain. Where the program stands: Immutep is reviewing its development strategy following the discontinuation of its Phase 3 TACTI-004 trial in head and neck cancer. The company has indicated the orphan designation may guide future decisions about advancing eftilagimod alfa in soft tissue sarcoma toward a late-stage neoadjuvant trial.

    Soft tissue sarcoma is not a single disease. It is a family of more than 70 distinct histologic subtypes arising from connective tissues including fat, muscle, nerves, tendons, and blood vessels throughout the body. They are rare in aggregate, accounting for roughly 1% of adult malignancies in the United States, with approximately 13,000 new diagnoses and 5,000 deaths annually. That rarity has been part of the problem: the treatment landscape has moved slowly in comparison to more common cancers, and many subtypes have seen no meaningful new approvals in decades.

    The current standard treatment for resectable soft tissue sarcoma is surgery, often with preoperative or postoperative radiation therapy. For higher-grade or larger tumors, neoadjuvant radiation before surgery is standard, but its response rate, measured by how much tumor the radiation kills before the surgeon removes it, has historically been modest. Pathologic response rates with radiotherapy alone typically produce median hyalinization and fibrosis around 15%. Chemotherapy is used in some settings but adds substantial toxicity with variable benefit.

    Immunotherapy has largely failed to show meaningful activity in most sarcoma subtypes. The complex, immunosuppressive tumor microenvironment of soft tissue sarcomas has made checkpoint inhibitors less effective here than in more immunogenic tumors like melanoma or lung cancer. The EFTISARC-NEO trial is testing a different approach: rather than simply blocking inhibitory immune checkpoints, it adds a drug designed to actively stimulate the immune system’s antigen-presenting machinery at the same time.

    On April 15, 2026, the FDA granted Orphan Drug Designation to eftilagimod alfa for soft tissue sarcoma, citing the EFTISARC-NEO data as the basis for the designation. This post covers what eftilagimod alfa is, what the trial actually showed, what the designation means in practice, and where this program sits relative to the broader and slowly evolving landscape of sarcoma treatment.

    What Eftilagimod Alfa Is: A LAG-3 Agonist, Not a Checkpoint Inhibitor

    Eftilagimod alfa (IMP321) is a soluble, recombinant form of LAG-3 (Lymphocyte Activation Gene-3), a protein expressed on the surface of activated T cells and natural killer cells. LAG-3 is commonly discussed in the context of immune checkpoint inhibitors, and several anti-LAG-3 antibodies (including relatlimab, which is approved in combination with nivolumab in melanoma) block LAG-3 on T cells to prevent exhaustion.

    Eftilagimod alfa works completely differently. Rather than blocking LAG-3 on T cells, it acts as an agonist for MHC class II molecules on antigen-presenting cells (APCs), including dendritic cells and macrophages. By binding MHC class II on APCs, it activates them to present tumor antigens more efficiently to both CD4+ and CD8+ T cells, stimulating a broad adaptive and innate immune response. The goal is to transform a cold, immunosuppressed tumor microenvironment into a hot one where the immune system can recognize and attack the cancer.

    This mechanism is complementary to pembrolizumab, which works by removing the inhibitory PD-1/PD-L1 brake on T cell activity. The hypothesis behind the EFTISARC-NEO combination is that eftilagimod alfa primes the immune system by activating APCs, pembrolizumab removes the brake on T cell activity, and radiotherapy releases tumor antigens by killing cancer cells, creating a coordinated, amplified anti-tumor immune response.

    Why soft tissue sarcoma has been resistant to immunotherapy The tumor microenvironment of soft tissue sarcoma is characterized by low mutational burden in most subtypes, sparse T cell infiltration, and high levels of immunosuppressive cells including tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells. This immunosuppressive landscape is why single-agent checkpoint inhibitors have shown limited activity in most sarcoma subtypes: removing the brake on T cells is less effective when there are few T cells present and an environment actively working to suppress them. Radiotherapy can partially address this by releasing tumor antigens and creating an inflammatory signal that recruits immune cells. Eftilagimod alfa is designed to amplify that immunological priming step by activating APCs to process and present those antigens more effectively. The combination hypothesis is therefore mechanistically grounded: prime with efti, release antigens with radiation, and remove the T cell brake with pembrolizumab.

    What Is Soft Tissue Sarcoma and Who Does It Affect?

    Soft tissue sarcomas are cancers that arise from mesenchymal tissue, the connective tissues that form the structural framework of the body. The major histologic groups include:

    • Undifferentiated pleomorphic sarcoma (UPS): Among the most common high-grade subtypes in adults. Aggressive with a high rate of local and distant recurrence.
    • Liposarcoma: Arises from fat tissue. Several subtypes with varying aggressiveness, from well-differentiated (low-grade) to dedifferentiated (high-grade).
    • Leiomyosarcoma: Arises from smooth muscle. Common in the uterus and retroperitoneum.
    • Synovial sarcoma: Affects primarily young adults and adolescents. One of the few subtypes with a recently approved immunotherapy (afami-cel, discussed below).
    • Myxofibrosarcoma: Common in the extremities of older adults. High local recurrence rate.

    EFTISARC-NEO specifically enrolled patients with grade 2 or 3, stage III sarcomas of the extremities or trunk with specific eligible histologies. The study was conducted at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, primarily funded through an approved grant from the Polish Medical Research Agency.

    Most soft tissue sarcomas present as painless masses. Diagnosis typically requires core needle biopsy and centralized pathologic review at a center with sarcoma expertise, because accurate subtype identification is critical for treatment planning. Management of high-grade resectable sarcoma typically involves a multidisciplinary team including surgical oncology, radiation oncology, and medical oncology.

    The EFTISARC-NEO Trial: What the Data Shows

    Trial design

    EFTISARC-NEO (NCT06128863) is a Phase 2, single-arm, single-center investigator-initiated study conducted at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw. It evaluates eftilagimod alfa administered concurrently with pembrolizumab (Keytruda, Merck) and standard radiotherapy as neoadjuvant treatment in patients with resectable soft tissue sarcoma.

    Eligible patients were adults aged 18 or older with ECOG performance status 0 or 1, grade 2 or 3 sarcomas, and eligible histologies including undifferentiated pleomorphic sarcoma, myxofibrosarcoma, pleomorphic liposarcoma, and pleomorphic leiomyosarcoma, among others. Tumors were required to be located in the deep extremities, girdles, or superficial trunk. No adjuvant treatment was permitted after surgery, with 24 months of regular follow-up.

    The treatment sequence: eftilagimod alfa and pembrolizumab administered during the 25-fraction radiotherapy course, followed by surgical resection. The primary endpoint was tumor hyalinization and fibrosis at the time of surgical resection.

    The primary endpoint: what tumor hyalinization and fibrosis actually measures

    Tumor hyalinization and fibrosis is a validated histopathologic endpoint in soft tissue sarcoma that quantifies the proportion of the tumor that has been replaced by scar tissue and devitalized cells after treatment, reflecting treatment-induced tumor cell kill. It is measured by a pathologist examining the surgical specimen after tumor removal. Higher hyalinization and fibrosis percentages indicate more extensive tumor destruction.

    This endpoint is clinically meaningful because it has been associated with improved outcomes in multiple sarcoma studies. A higher pathologic response rate at surgery predicts better overall survival and recurrence-free survival compared to lower response rates, even though it is measured at a single timepoint. It is analogous in concept to pathologic complete response (pCR) used as a surrogate endpoint in breast cancer neoadjuvant trials.

    The historical benchmark with radiotherapy alone in comparable patient populations is approximately 15% median hyalinization and fibrosis. The EFTISARC-NEO trial was designed with an ambitious prespecified threshold: the trial would be considered successful if the median exceeded 35%.

    Results

    OutcomeResultContext
    Evaluable patients (full analysis)38Target enrollment completed January 2025
    Median tumor hyalinization/fibrosis51.5%vs 35% prespecified target; vs ~15% historical with RT alone
    Patients achieving 35% or greaterMajority of evaluable patientsExceeded prespecified threshold
    Consistency across subtypesYesBenefit seen across multiple STS histologies
    Grade 3 or higher toxicity from efti or pembrolizumab0No high-grade immune-related toxicity
    Surgical delays related to treatment0All patients proceeded to planned surgery
    Translational immune dataShowed immune activation consistent with mechanism of actionAPC activation, CD4+ and CD8+ T cell engagement

    Source: ESMO Congress 2025 Proffered Paper presentation. CTOS 2025 Annual Meeting Oral Presentation. Immutep press release April 15, 2026.

    The 51.5% median is more than a 3-fold increase over the 15% historical benchmark. The fact that no patients had their surgery delayed due to treatment toxicity is a practical clinical finding that matters in the neoadjuvant setting, where surgery timing is part of the overall treatment plan. The translational data showing immune activation consistent with the proposed mechanism of action, including evidence of APC engagement and downstream T cell responses in the tumor microenvironment, supports the mechanistic hypothesis rather than simply showing an empirical effect.

    Full detailed results from the complete 38-patient analysis were presented at ESMO Congress 2025 as a Proffered Paper, a higher-tier presentation format at ESMO, and at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting.

    What Orphan Drug Designation Means and What It Does Not

    FDA Orphan Drug Designation is granted to drugs intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the United States. Soft tissue sarcoma meets this threshold.

    The designation provides:

    • 7 years of market exclusivity after approval, protecting against generic or biosimilar competition
    • Tax credits covering 25% of qualified clinical trial costs
    • Fee waivers for FDA application fees
    • Enhanced regulatory guidance and potential for more frequent FDA interaction during development
    • Eligibility for Orphan Drug grants for qualifying organizations

    The European Medicines Agency had already granted a similar designation for eftilagimod alfa in soft tissue sarcoma before the FDA designation, establishing parallel orphan status on both sides of the Atlantic.

    What the designation does not mean: it is not approval, not a guarantee of approval, and does not reduce the evidence standard required for approval. A drug with Orphan Drug Designation still needs to demonstrate substantial evidence of safety and efficacy in adequate and well-controlled clinical studies to be approved. The designation is a development incentive, not a regulatory shortcut.

    The TACTI-004 Context: Why This Is a Pivotal Moment for Eftilagimod Alfa

    Understanding the significance of the soft tissue sarcoma program requires understanding what happened in Immutep’s flagship program.

    The TACTI-004 trial was a Phase 3 study evaluating eftilagimod alfa in combination with pembrolizumab for first-line treatment of head and neck squamous cell carcinoma (HNSCC), the largest and most advanced clinical program in eftilagimod alfa’s development history. In early 2026, Immutep announced the discontinuation of TACTI-004, citing the emerging competitive landscape in first-line HNSCC where multiple approved combination regimens had raised the bar for demonstrating meaningful superiority.

    The discontinuation was a significant setback for the broader eftilagimod alfa program. However, the company has been careful to distinguish the HNSCC competitive context from the sarcoma setting, where there is no equivalent competitive landscape and the therapeutic need remains largely unmet.

    For soft tissue sarcoma specifically, the evidence picture is different. The EFTISARC-NEO results are in a disease with no approved immunotherapy in the neoadjuvant setting, limited treatment advances in recent years, and a validated pathologic endpoint with prognostic relevance. The Orphan Drug Designation provides development incentives that could support moving toward a formal registrational trial.

    The Broader Sarcoma Treatment Landscape: Where This Fits

    The soft tissue sarcoma treatment landscape has seen modest but meaningful recent progress after years of relative stagnation.

    The most directly relevant recent approval is afami-cel (Tecelra, Adaptimmune), the first T cell receptor-engineered cell therapy approved by the FDA, which received approval in August 2024 for unresectable or metastatic synovial sarcoma in adults and adolescents 16 or older after prior treatment. Afami-cel targets MAGE-A4, an antigen expressed on synovial sarcoma cells, and produced an overall response rate of 39% in the pivotal trial. It represents the first approved immunotherapy in soft tissue sarcoma, opening the door to immune-based approaches in a tumor type where they had previously largely failed.

    Eftilagimod alfa is pursuing a different subtype of sarcoma, a different treatment setting (neoadjuvant rather than metastatic), and a different mechanism (APC activation rather than T cell receptor engineering). The two programs are not in competition; they address different clinical scenarios within the same broad disease category.

    Other relevant pipeline programs in soft tissue sarcoma include olaratumab, which is being re-evaluated after its initial Phase 3 failure, and multiple combinations exploring CDK4/6 inhibitors for well-differentiated and dedifferentiated liposarcoma, which overexpresses CDK4.

    What This Means for Patients and Oncologists

    For patients currently being treated for resectable soft tissue sarcoma, eftilagimod alfa is investigational. It is not approved and is not available outside of clinical trials. The EFTISARC-NEO trial completed enrollment in January 2025 and is currently in the follow-up period. Immutep has indicated that the Orphan Drug Designation may support planning a late-stage neoadjuvant trial, but no registration trial has been announced or started.

    For patients interested in sarcoma clinical trial options, ClinicalTrials.gov is the primary resource for identifying open enrollment studies. The Sarcoma Foundation of America and the Sarcoma Alliance maintain patient-facing resources on sarcoma subtypes, treatment options, and clinical trial access. Sarcoma care is highly specialized, and management at a National Cancer Institute-designated cancer center or a dedicated sarcoma program is strongly recommended for diagnosis and treatment planning.

    For clinicians, the EFTISARC-NEO results represent the strongest prospective data for an immunotherapy-containing regimen in resectable high-grade soft tissue sarcoma to date, though the single-arm, single-center Phase 2 design limits direct actionability without confirmatory data. The translational correlates presented at ESMO 2025 and CTOS 2025 supporting the proposed mechanism of action are a meaningful addition to the evidence base.

    For context on how the FDA has been using orphan drug and rare disease designations alongside other regulatory tools to accelerate rare disease drug development in 2026, see our post on the UX111 gene therapy for Sanfilippo syndrome, which holds multiple FDA rare disease designations and is currently under review, and our post on the first gene therapy for genetic deafness, which was approved under the Rare Pediatric Disease PRV program.

    Sources

    Immutep Orphan Drug Designation press release: Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma. GlobeNewswire. April 15, 2026.

    Immutep company website: Eftilagimod Alfa Pipeline. immutep.com.

    EFTISARC-NEO trial registration: NCT06128863. ClinicalTrials.gov.

    Targeted Oncology ODD coverage: FDA Grants Orphan Drug Designation to Eftilagimod Alfa for Soft Tissue Sarcoma. targetedonc.com. April 2026.

    OncLive primary endpoint coverage: Eftilagimod Alfa/Radiotherapy/Pembrolizumab Yields Favorable Hyalinization/Fibrosis in Soft Tissue Sarcoma. onclive.com. May 2025.

    CancerNetwork coverage: Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma. cancernetwork.com. May 2025.

    Targeted Oncology Phase 2 results: EFTISARC-NEO Trial Meets Primary End Point in Soft Tissue Sarcoma. targetedonc.com. May 2025.

    Afami-cel FDA approval: FDA approves afami-cel for synovial sarcoma. FDA.gov. August 2024.

    FDA Orphan Drug Designation program: Orphan Drug Designations and Approvals. FDA.gov.

    Orphan Drug market exclusivity and incentives: Designating an Orphan Product. FDA.gov.

    LAG-3 biology reference: LAG-3 and its role in cancer immunotherapy. PMC7938019.

    STS tumor microenvironment: Tumor Microenvironment in Soft Tissue Sarcoma. PMC9912345.

    Hyalinization/fibrosis as prognostic endpoint: Pathologic Response in Soft Tissue Sarcoma. PMC4580342.

    Soft tissue sarcoma overview: Soft Tissue Sarcoma. American Cancer Society.

    Patient resources: Sarcoma Foundation of America | Sarcoma Alliance | ClinicalTrials.gov: Soft Tissue Sarcoma | NCI Sarcoma Information

    Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. Eftilagimod alfa is investigational and not currently FDA-approved for soft tissue sarcoma or any other indication in the United States. Treatment decisions for soft tissue sarcoma should be made in consultation with a qualified oncologist at a center with sarcoma expertise.
  • The FDA Approved Foundayo. It Also Required These Post-Marketing Studies. Here Is What That Means and Why It Is Normal Practice.

    The FDA Approved Foundayo. It Also Required These Post-Marketing Studies. Here Is What That Means and Why It Is Normal Practice.

    📌 The essentials Foundayo (orforglipron) was approved by the FDA on April 1, 2026 as the first non-peptide, small molecule oral GLP-1 receptor agonist for chronic weight management. It was approved 50 days after NDA submission under the Commissioner’s National Priority Voucher (CNPV) program, the fastest approval of a new molecular entity since 2002. As part of the FDA approval letter, Eli Lilly is required to conduct several post-marketing studies. Per the FDA approval letter, these include: evaluation of major adverse cardiovascular events (MACEs) and drug-induced liver injury (DILI); assessment of delayed gastric emptying and aspiration risk; a lactation study to measure drug concentrations in breast milk; pediatric trials in patients aged 6 to 12; and pregnancy registry data. The FDA is also requiring enhanced pharmacovigilance for drug-induced liver injury for 5 years following approval, including expedited reporting of serious cases. Lilly has also separately released ACHIEVE-4 trial data showing non-inferior MACE risk compared to insulin glargine, which directly addresses the cardiovascular monitoring requirement. What this does not mean: post-marketing study requirements are routine for obesity medications and do not reflect a finding that the drug is unsafe. Foundayo was approved based on the ATTAIN clinical program data. The post-marketing studies reflect normal FDA practice of continuing safety surveillance after approval, particularly for a new molecular class with limited long-term data.

    Foundayo (orforglipron) was the most talked-about obesity drug approval of 2026. Not just because of what it is, the first oral GLP-1 receptor agonist that does not require a peptide injection and has no food or water restrictions, but because of how fast it happened. The FDA approved it 50 days after Eli Lilly submitted the NDA, making it the fastest approval of a new molecular entity since 2002, and the first new molecular entity approved under the Commissioner’s National Priority Voucher program.

    What received less coverage in that story is a standard part of every major drug approval: the FDA’s post-marketing study requirements. These are the conditions attached to the approval letter specifying additional clinical studies Lilly must conduct now that the drug is on the market. A Reuters report noted some of these requirements shortly after the approval. This post looks directly at the FDA approval letter, explains what each requirement is and why it exists, and puts the requirements in context for the broader GLP-1 obesity treatment landscape.

    For a full overview of what Foundayo is, how orforglipron works, and what the ATTAIN clinical trial data showed, see our main post: Foundayo: The First Once-Daily GLP-1 Pill for Weight Loss.

    What Orforglipron Is and Why It Is Different

    Orforglipron is a small molecule, non-peptide GLP-1 receptor agonist. Every GLP-1 receptor agonist currently approved in the United States before Foundayo, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity), is based on a peptide molecule, a chain of amino acids structurally similar to the natural GLP-1 hormone. Because peptides are broken down in the stomach, most of these drugs are injectable. The one exception, Rybelsus (oral semaglutide), requires fasting for 30 minutes and a small amount of water to achieve adequate absorption.

    Orforglipron is fundamentally different. It is a small organic molecule, not a peptide, that binds to and activates the same GLP-1 receptor. Its small molecule structure allows it to survive oral digestion without the absorption restrictions that peptide-based oral semaglutide requires. It can be taken at any time of day, with or without food, and without water restrictions.

    This is a genuine pharmacological advance. The practicality difference between taking a once-weekly injection, taking a pill at a specific time under fasting conditions, and taking a pill whenever you want matters for real-world adherence, particularly among the more than 90% of eligible patients who are not currently on any GLP-1 therapy.

    The ATTAIN clinical program demonstrated that in the ATTAIN-1 trial, patients taking the highest dose of Foundayo who stayed on treatment lost an average of 27.3 pounds (12.4% of body weight) compared to 2.2 pounds (0.9%) with placebo. Across all trial completers regardless of dose escalation, average weight loss was 25 pounds (11.1%) versus 5.3 pounds (2.1%) with placebo. The drug also showed reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure.

    What Post-Marketing Studies Are and Why They Are Routine

    Before getting into the specific requirements for Foundayo, it is worth explaining what post-marketing study requirements actually are, because the framing of “FDA requires studies” can sound more alarming than it is.

    Every major drug approval, particularly for new molecular entities in new drug classes, comes with post-marketing commitments and requirements. These fall into two categories:

    Post-marketing commitments (PMCs): voluntary agreements where the sponsor agrees to conduct additional studies, often to explore dosing, new populations, or drug interactions.

    Post-marketing requirements (PMRs): studies the FDA requires by law because specific safety questions cannot be adequately answered through nonclinical data or observational surveillance alone. They are written into the approval letter.

    The distinction matters: PMRs do not mean the drug has a safety problem. They mean the FDA identified specific questions about safety in populations or settings that were not fully characterized in the pivotal trial program, and that randomized, controlled prospective data is needed to answer those questions properly. This is how responsible post-market surveillance of new drug classes works.

    GLP-1 receptor agonists as a class have been subject to ongoing FDA safety monitoring since the class was first approved, including reviews of suicidal ideation reports (for which the FDA ultimately concluded in 2024 that the available evidence does not support a causal relationship between GLP-1 receptor agonists and suicidal behavior), thyroid cancer signals, and pancreatitis risk. Foundayo’s post-marketing requirements build on this established framework.

    The Specific Post-Marketing Requirements for Foundayo

    Based on the FDA approval letter and coverage of the approval letter contents, the following post-marketing study requirements are in place for Foundayo:

    1. Cardiovascular outcomes (MACEs)

    What is required: A prospective randomized trial evaluating major adverse cardiovascular events (MACEs), specifically heart attack, stroke, cardiovascular death, and unstable angina requiring hospitalization.

    Why this is required: The FDA requires all new diabetes and obesity drugs to demonstrate cardiovascular safety through adequate CVOT (cardiovascular outcomes trial) data. The pivotal ATTAIN trials were designed to demonstrate weight loss efficacy and were not powered or designed as cardiovascular outcomes studies. The FDA therefore requires a dedicated CVOT to characterize the full cardiovascular risk-benefit profile of orforglipron in a larger population over longer follow-up.

    Current status: Lilly has already released results from the Phase 3 ACHIEVE-4 trial (NCT05803421), which evaluated orforglipron versus insulin glargine in patients with type 2 diabetes. ACHIEVE-4 showed non-inferior risk for MACEs compared to insulin glargine and detected no safety signal for drug-induced liver injury. Lilly has indicated it plans to submit an NDA for Foundayo in type 2 diabetes by the end of Q2 2026, supported by this data. The ACHIEVE-4 results partially address the cardiovascular monitoring requirement, though the FDA will specify the scope of ongoing data requirements.

    2. Drug-induced liver injury (DILI)

    What is required: Enhanced pharmacovigilance for drug-induced liver injury for 5 years following approval, including expedited reporting of serious cases and periodic cumulative safety analyses.

    Why this is required: New small molecule drugs, particularly those in new molecular classes, are monitored carefully for hepatotoxicity signals that may not have been apparent in pivotal trials. The ACHIEVE-4 trial found no safety signal for liver injury, but the FDA is requiring systematic prospective surveillance across the broader post-market population.

    Context: Drug-induced liver injury is one of the most common reasons for post-market drug withdrawals and is a priority safety monitoring target for the FDA across drug classes. The 5-year enhanced surveillance period is a standard precautionary measure for new molecular entities.

    3. Delayed gastric emptying and aspiration risk

    What is required: Assessment of the drug’s effects on gastric emptying rate and associated aspiration risk, particularly relevant in the context of anesthesia and sedation procedures.

    Why this is required: GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action, and this effect has clinical implications for patients undergoing procedures requiring anesthesia or sedation. The American Society of Anesthesiologists has issued guidance on GLP-1 agonists in the perioperative setting, recommending holding these medications before procedures. The FDA’s requirement for orforglipron specifically is to characterize the gastric emptying effect of the oral formulation, which may have different pharmacokinetics than injectable versions.

    4. Lactation study

    What is required: A study measuring drug concentrations in breast milk in nursing mothers.

    Why this is required: The pivotal trials excluded pregnant and breastfeeding women. The FDA requires a lactation study to determine the extent to which orforglipron is transferred into breast milk, as this directly informs prescribing decisions for women who are breastfeeding and clinicians counseling them on the drug’s safety in this setting.

    5. Pediatric trials (ages 6 to 12)

    What is required: Clinical trials in pediatric patients aged 6 to 12 years with obesity.

    Why this is required: The Pediatric Research Equity Act (PREA) generally requires sponsors to study new drugs in pediatric populations unless a waiver is granted. The FDA waived the under-6 age group, citing limited expected use and therapeutic benefit in very young children. The 6 to 12 age group is included given that childhood and adolescent obesity is a significant clinical problem and clinicians will eventually prescribe this drug in younger patients.

    6. Pregnancy registry

    What is required: A structured pregnancy exposure registry to capture outcomes in women who become pregnant while taking Foundayo.

    Why this is required: GLP-1 medications should be discontinued before attempting conception because of potential fetal effects, but unintended pregnancies during treatment are well documented across this drug class. The pregnancy registry will systematically capture data on fetal outcomes in women with inadvertent first-trimester exposure, building a real-world safety database that cannot be generated from controlled trials.

    Hair loss: a side effect, not a post-marketing study requirement The stub post on this topic framed hair loss as equivalent to the post-marketing study requirements above. This needs clarification. Hair loss is listed as a common side effect in the Foundayo prescribing information, alongside nausea, constipation, diarrhea, and other GI effects. It was observed in the ATTAIN trials and is included in the approved label. It is not a specific named post-marketing study requirement in the same category as the CVOT or DILI monitoring. Hair loss has been observed with GLP-1 medications more broadly and is believed to be related to the physiological stress of rapid weight loss (telogen effluvium) rather than a direct drug effect. Patients who experience hair loss on Foundayo should discuss it with their prescriber; it is typically reversible as weight stabilizes.

    Why This Pattern Is Consistent With the CNPV Approval Context

    The speed of Foundayo’s approval under the CNPV program, 50 days from NDA submission, is directly relevant to understanding why the post-marketing study package is robust. The CNPV program compresses FDA review timelines dramatically but does not reduce the evidentiary standard for approval. For a novel molecular entity in a new drug class, some safety questions that would normally be answered in a longer review process are instead addressed through post-market commitments.

    This is not unique to Foundayo. Wegovy HD (semaglutide 7.2 mg), which was also approved under the CNPV program, similarly came with post-marketing monitoring requirements. The CNPV program approval speed and the post-marketing study requirements are two parts of the same regulatory approach: approve based on strong efficacy and acceptable safety from the clinical program, then require prospective data to fill the remaining gaps systematically.

    The FDA’s approach to Foundayo reflects a broader evolution in how it handles obesity drug safety. After the experience with earlier obesity drugs including sibutramine (withdrawn for cardiovascular risk) and fenfluramine (withdrawn for valvular heart disease), the FDA has taken a systematically cautious approach to post-market safety surveillance for this class, requiring dedicated CVOT data and structured monitoring programs.

    What Patients Taking Foundayo Should Know

    If you are taking or considering Foundayo for weight management, the post-marketing study requirements do not indicate that the drug is unsafe. They indicate that the FDA is conducting the normal, responsible surveillance that accompanies every major new drug class approval.

    The safety profile documented in the ATTAIN trials showed that the most common side effects were gastrointestinal, including nausea, constipation, diarrhea, vomiting, and abdominal pain. These are consistent with the established profile of the GLP-1 receptor agonist class. Hair loss was also reported and is typically temporary.

    Key practical points:

    • Foundayo should be discontinued at least 2 months before planned conception, consistent with guidance across the GLP-1 class. Effective contraception during treatment is recommended.
    • Inform your anesthesia provider that you are taking Foundayo before any scheduled procedure requiring general anesthesia or deep sedation, as the gastric emptying effect is clinically relevant in this setting.
    • Report any symptoms of liver injury, including unusual fatigue, jaundice, or upper right abdominal pain, to your prescriber promptly.
    • Do not use Foundayo with other GLP-1 receptor agonists.

    For more on how GLP-1 medications interact with reproductive health considerations, see our post on GLP-1 medications, PCOS, and the fertility and pregnancy evidence in 2026.

    Sources

    FDA approval announcement: FDA Approves First New Molecular Entity Under National Priority Voucher Program. FDA.gov. April 1, 2026.

    FDA approval letter: Foundayo (orforglipron) NDA approval letter. accessdata.fda.gov. April 1, 2026.

    Lilly approval press release: FDA Approves Lilly’s Foundayo (orforglipron). investor.lilly.com. April 1, 2026.

    Clinical Trials Arena post-marketing coverage: Lilly debuts more Foundayo data as FDA requests post-marketing trials. clinicaltrialsarena.com. April 16, 2026.

    Pharmacally post-marketing requirements detail: FDA Requires Extensive Postmarketing Safety Data for Foundayo. pharmacally.com. April 2026.

    Foundayo drug history: Foundayo (orforglipron) FDA Approval History. drugs.com.

    ACHIEVE-4 trial registration: NCT05803421. ClinicalTrials.gov.

    FDA GLP-1 and suicidal ideation review: Information About Suicidal Thoughts, Behavior, and GLP-1 Receptor Agonists. FDA.gov.

    Post-marketing studies FDA guidance: Postmarketing Studies and Clinical Trials: Guidance for Industry. FDA.gov.

    GLP-1 gastric emptying clinical review: Delayed Gastric Emptying and GLP-1 Receptor Agonists. PMC10183139.

    PREA pediatric requirement: Pediatric Research Equity Act. FDA.gov.

    DILI overview: Drug-Induced Liver Injury. StatPearls. NCBI.

    ASA GLP-1 perioperative guidance: American Society of Anesthesiologists Guidance on GLP-1 Receptor Agonists. asahq.org.

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about obesity treatment, including whether Foundayo is appropriate for your situation, should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, current medications, and weight management goals.
  • The FDA Just Removed Boxed Warnings From Six Hormone Therapy Products. Here Is What Changed, What Stayed, and Why It Matters.

    The FDA Just Removed Boxed Warnings From Six Hormone Therapy Products. Here Is What Changed, What Stayed, and Why It Matters.

    📌 The essentials On February 12, 2026, the FDA approved drug labeling changes to six menopausal hormone therapy products, removing risk statements related to cardiovascular disease, breast cancer, and probable dementia from their boxed warnings. This is the first batch of approvals. At the FDA’s request, 29 drug companies have submitted proposed labeling changes, with additional approvals expected as submissions are reviewed. The six products affected: Bijuva (estradiol and progesterone), Divigel (estradiol gel), Cenestin (synthetic conjugated estrogens A), Enjuvia (synthetic conjugated estrogens B), Prometrium (progesterone), and Estring (estradiol vaginal system). What was NOT removed: the boxed warning for endometrial cancer remains on systemic estrogen-alone products. This is a clinically important retained warning that all prescribers and patients should be aware of. Context: the FDA initiated this label review in November 2025 following a comprehensive scientific literature review, an expert advisory panel in July 2025, and a public comment period. The 29-company label update process is ongoing.

    Menopausal hormone therapy has had a complicated two decades in American medicine. In the early 2000s, the Women’s Health Initiative (WHI), a landmark landmark trial, reported findings that were widely interpreted as showing hormone therapy increased risks of breast cancer, heart disease, stroke, and blood clots. The FDA added boxed warnings to hormone therapy products reflecting those risks. Prescribing dropped dramatically, and it never fully recovered.

    The scientific community has spent years re-examining those findings. The primary methodological critique has been consistent: the average age of WHI participants was 63, more than a decade past the average age of menopause onset. The formulation used (conjugated equine estrogen plus medroxyprogesterone acetate, a synthetic progestin) is not representative of current prescribing, which increasingly favors body-identical hormones. And subsequent analyses specifically in younger women who started HRT closer to menopause onset showed a substantially different risk profile.

    On February 12, 2026, the FDA acted on that updated evidence. It approved the removal of cardiovascular disease, breast cancer, and probable dementia risk statements from the boxed warnings of six hormone therapy products. The action is the first step of a broader process affecting 29 drug products.

    What a Boxed Warning Is and Why Its Removal Matters

    A boxed warning is the FDA’s most prominent safety communication on a drug label. It appears inside a bold black border at the top of the prescribing information and is reserved for serious or life-threatening risks. Its presence signals to prescribers that the drug carries risks serious enough to warrant special consideration and monitoring.

    For many prescribers and patients, a boxed warning is functionally a deterrent. The presence of a cancer warning or heart disease warning on hormone therapy labels has contributed to underutilization for more than two decades. The utilization gap is stark: in 2020, approximately 41 million U.S. women were between ages 45 and 64, yet only about 2 million women ages 46 to 65 received a hormone therapy prescription. That is roughly 1 in 20.

    Removing those specific risk statements from the boxed warning reflects the FDA’s conclusion, after comprehensive scientific review, that the evidence no longer supports placing cardiovascular disease, breast cancer, and probable dementia in the most prominent warning position on the label.

    What Was Removed and What Was Retained

    This distinction is clinically critical and was largely absent from most coverage of this announcement.

    Removed from boxed warnings (for the six approved products):

    • Risk statements related to cardiovascular disease
    • Risk statements related to breast cancer
    • Risk statements related to probable dementia

    Retained and not changed:

    • The boxed warning for endometrial cancer remains on systemic estrogen-alone products. This warning is not being removed because it reflects a well-established, causal biological relationship: unopposed estrogen in women with an intact uterus increases the risk of endometrial hyperplasia and endometrial cancer. This is why women with an intact uterus who use systemic estrogen-alone therapy require concurrent progestogen. This warning is not a legacy artifact of the WHI. It reflects established reproductive endocrinology and has not been reconsidered in this process.
    • Contraindications remain in the prescribing information for all updated products, including active arterial thromboembolic disease (stroke, myocardial infarction), known or suspected breast cancer, known or suspected estrogen-dependent neoplasia, undiagnosed abnormal uterine bleeding, active liver dysfunction, and known hypersensitivity.
    Why the endometrial cancer warning staying matters Estrogen stimulates growth of the uterine lining. Without progesterone or progestogen to counteract that stimulation, prolonged unopposed estrogen exposure in women with a uterus can cause endometrial hyperplasia and increase the risk of endometrial cancer. This is not a disputed risk. It is a well-characterized biological mechanism that has been known since the 1970s. The current label update specifically preserves this warning for systemic estrogen-alone products (such as estradiol patches, oral estrogens, and estradiol gels like Divigel). Women with an intact uterus who use systemic estrogen therapy must be prescribed a progestogen alongside it. This requirement does not change with the February 2026 label updates.

    The Scientific Evidence Behind the Label Changes

    The FDA’s decision followed a systematic process that included an expert advisory panel in July 2025, a comprehensive literature review, and a public comment period. The relevant evidence base is substantial and has been building for years.

    The WHI reanalysis and the timing hypothesis

    The Women’s Health Initiative enrolled women with an average age of 63. When researchers reanalyzed the WHI data stratifying by age at enrollment and time since menopause, a different picture emerged. Women who started HRT within 10 years of menopause onset or before age 60 showed different outcomes than those who started more than 10 years post-menopause. This is sometimes called the “timing hypothesis” or “window of opportunity.”

    The Kronos Early Estrogen Prevention Study (KEEPS) enrolled women aged 42 to 58 within 36 months of their final menstrual period and found that low-dose oral or transdermal estradiol started early in the menopausal transition did not increase cardiovascular risk over four years.

    The Early versus Late Intervention Trial with Estradiol (ELITE) randomized women to estradiol or placebo based on time since menopause (fewer than 6 years, or more than 10 years). It found that estradiol slowed progression of subclinical atherosclerosis in women who started within 6 years of menopause but not in those who started later, directly supporting the timing hypothesis.

    The Menopause Society’s 2022 position statement concluded that the benefits of hormone therapy outweigh the risks for most healthy symptomatic women who begin treatment under age 60 or within 10 years of menopause, and that the WHI data should not be applied indiscriminately to all hormone therapy users.

    The FDA’s February 2026 label update represents the regulatory translation of this accumulated body of evidence.

    What the updated labels say about timing

    The FDA’s updated labeling recommendation is to start systemic HRT within 10 years of menopause onset or before age 60. This is not an absolute contraindication for later initiation, but it is a clinical guidance point that the label will now include explicitly.

    The benefit claims: what the evidence actually supports

    The HHS fact sheet accompanying this announcement cited risk reductions including cardiovascular diseases by up to 50%, Alzheimer’s disease by 35%, and bone fractures by 50 to 60%. These figures come from observational analyses and secondary endpoint analyses from the relevant literature. They represent the upper estimates of potential benefit from studies of women who initiated HRT at younger ages and are not uniformly established as causal effect sizes across all formulations and populations. The fracture reduction data is the most consistently supported. The cardiovascular benefit in the timing window is biologically plausible and supported by the evidence above. The Alzheimer’s protection data is promising but still the subject of ongoing research. The appropriate interpretation of these figures is that they reflect the potential magnitude of benefit in women who use HRT appropriately, not guaranteed outcomes for every individual patient.

    Which Products Are Affected and Their Updated Labels

    The six products in the first batch of approved labeling changes represent all four major categories of menopausal HRT:

    ProductCategoryActive ingredientUpdated label
    BijuvaSystemic combination (estrogen plus progestogen)Estradiol and progesteroneLink
    DivigelSystemic estrogen-alone (topical gel)EstradiolLink
    CenestinSystemic estrogen-alone (oral)Synthetic conjugated estrogens ALink
    EnjuviaSystemic estrogen-alone (oral)Synthetic conjugated estrogens BLink
    PrometriumSystemic progestogen-aloneProgesterone (micronized)Link
    EstringTopical vaginal estrogen (ring)Estradiol vaginal systemLink

    The remaining 23 drug companies that submitted proposed labeling changes are still in the review process. Their products will be updated as submissions are approved. The FDA’s menopausal hormone therapies updated prescribing information page will track additional products as they are approved.

    What This Means for Women and Clinicians

    For women currently using or considering HRT

    The removal of boxed warnings for cardiovascular disease, breast cancer, and probable dementia does not mean these risks are zero. It means the FDA has concluded that the evidence does not support placing them in the most prominent risk-warning position for the indicated population (women using HRT appropriately, typically within 10 years of menopause onset and before age 60).

    HRT remains an individualized decision that should account for personal risk factors including:

    • Personal or family history of breast cancer
    • History of blood clots, stroke, or cardiovascular disease
    • Liver disease
    • Undiagnosed vaginal bleeding
    • Time since menopause and age at initiation

    The Menopause Society’s practitioner finder can help identify clinicians with menopause medicine certification who are equipped to discuss the updated evidence and individual risk profiles.

    For clinicians

    The label changes affect prescribing information and patient counseling conversations. Women who have avoided HRT because of the boxed warnings may now re-engage with the question, and clinicians should be prepared to have evidence-based conversations about individualized benefit-risk assessment. The retained endometrial cancer warning for estrogen-alone products, the continued contraindications, and the timing guidance are all still present in the label and remain clinically operative.

    What has not changed

    HRT still requires a prescription. Contraindications still apply. The timing guidance (within 10 years of menopause onset or before age 60 for systemic HRT) is a recommendation, not an absolute cutoff. Women with an intact uterus still need progestogen with systemic estrogen. The conversations between clinician and patient remain the appropriate framework for HRT decisions.

    For related coverage on how this label change fits into the broader reassessment of hormone therapy in women’s health, see our posts on vaginal estrogen therapy safety in endometrial cancer survivors, hormone therapy underuse in women with premature ovarian insufficiency, and new 2026 cervical cancer screening guidelines allowing self-collection.

    Sources

    FDA press announcement: FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. FDA.gov. February 12, 2026.

    HHS announcement (November 2025): HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. FDA.gov. November 10, 2025.

    HHS fact sheet: FACT SHEET: FDA Initiates Removal of “Black Box” Warnings from Menopausal Hormone Replacement Therapy Products. HHS.gov. November 10, 2025.

    FDA updated prescribing information tracker: Menopausal Hormone Therapies with Updated Prescribing Information. FDA.gov.

    Updated label: Bijuva: accessdata.fda.gov.

    Updated label: Divigel: accessdata.fda.gov.

    Updated label: Cenestin: accessdata.fda.gov.

    Updated label: Enjuvia: accessdata.fda.gov.

    Updated label: Prometrium: accessdata.fda.gov.

    Updated label: Estring: accessdata.fda.gov.

    Contemporary OB/GYN coverage: FDA updates labels on multiple menopausal hormone therapies. contemporaryobgyn.net. February 12, 2026.

    Pharmacy Times coverage: FDA Approves Drug Labeling Changes to 6 Menopausal Hormone Therapy Products. pharmacytimes.com. 2026.

    Prism News coverage: FDA narrows boxed warnings for six menopausal hormone therapies. prismnews.com. February 13, 2026.

    KEEPS trial: Harman SM et al. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric. 2005. PMC3678904.

    ELITE trial: Hodis HN et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. N Engl J Med. 2016.

    Menopause Society 2022 position statement: The 2022 Menopause Society Position Statement on Hormone Therapy. menopause.org.

    WHI background: Women’s Health Initiative. National Heart, Lung, and Blood Institute.

    Menopause Society practitioner finder: Find a Menopause Healthcare Practitioner.

    Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about hormone therapy should be made in consultation with a qualified healthcare provider who can evaluate your individual health history, risk factors, and symptom burden.

  • Cancer Outcomes Are Worse for LGBTQ+ Patients. The Research Infrastructure to Address That Is Just Getting Started.

    Cancer Outcomes Are Worse for LGBTQ+ Patients. The Research Infrastructure to Address That Is Just Getting Started.

    📌 What this post covers In 2024, the American Cancer Society published its first dedicated report on cancer in LGBTQ+ people, and the findings were stark: LGBTQ+ individuals are more likely to develop certain cancers, face more barriers to screening and diagnosis, and report worse experiences of care than their heterosexual and cisgender counterparts. A central driver of these disparities is a problem that sounds administrative but has real clinical consequences: most health systems still do not routinely collect sexual orientation and gender identity (SOGI) data. Without that data, oncology teams cannot identify these patients, tailor their care, or study outcomes in any systematic way. This post covers what the evidence shows about LGBTQ+ cancer disparities, why the data collection gap is central to the problem, and what the research community is doing to address it, including a new national research center funded by the American Cancer Society specifically to improve outcomes in this population.

    Approximately 7.6% of U.S. adults identify as LGBT or something other than heterosexual, according to the most recent Gallup data. Applied to the ACS’s 2024 estimate of more than 2 million new cancer diagnoses annually, that translates to approximately 152,000 sexual and gender minority (SGM) people receiving a cancer diagnosis each year in the United States. That is a large population. It is also a population for which the evidence base is thin, clinical guidelines are largely unadapted, and routine care is frequently inadequate.

    This is not a new observation. The National Institutes of Health formally designated sexual and gender minorities as a population experiencing health disparities for research purposes in 2016. The Institute of Medicine called for increased research investment in SGM health in 2011. A decade and a half later, the research infrastructure to support that work is only now beginning to reach the scale the problem requires.

    What the Evidence Shows: LGBTQ+ Cancer Disparities Are Real and Understudied

    The 2024 ACS Cancer Facts and Figures Special Section on Cancer in LGBTQ+ People is the most comprehensive synthesis of this evidence to date. Its findings point to disparities across three dimensions: higher cancer risk, lower screening uptake, and worse experiences of care.

    Higher cancer risk driven by modifiable factors

    LGBTQ+ individuals have higher rates of several modifiable cancer risk factors compared to heterosexual and cisgender populations. The disparities are not uniform across all subgroups, but the patterns are consistent enough to be clinically meaningful.

    Tobacco use: LGBTQ+ individuals have higher rates of smoking than the general population. Tobacco is the leading preventable cause of cancer, responsible for at least 30% of all cancer deaths. Higher tobacco prevalence in LGBTQ+ communities is a downstream consequence of stress, social marginalization, and targeted marketing by the tobacco industry to LGBTQ+ communities over decades.

    Alcohol use: Lesbian, gay, and bisexual individuals are more likely to engage in heavy alcohol consumption than heterosexual peers, according to the ACS report. Alcohol use increases risk for liver, esophageal, colorectal, oral, stomach, and breast cancers.

    Excess body weight: Lesbian and bisexual individuals assigned female at birth are more likely to have excess body weight than their heterosexual counterparts, with lower rates of leisure-time physical activity contributing to the disparity. Excess weight is a risk factor in at least 12 types of cancer.

    HIV status: Gay and bisexual men have substantially higher rates of HIV infection, and people living with HIV have elevated risk for multiple cancers, including non-Hodgkin lymphoma, Kaposi sarcoma, and anal cancer, as well as certain non-AIDS-defining cancers.

    The ACS authors were careful to frame these risk factors as products of social and structural conditions, not inherent properties of LGBTQ+ identity. The minority stress model, which documents how chronic exposure to discrimination, stigma, and social marginalization produces downstream health consequences, is the framework that best explains these patterns.

    Lower screening rates and later-stage diagnoses

    The disparities are not limited to risk exposure. They extend to cancer detection.

    At the 2024 ASCO Annual Meeting, researchers presented findings from a study of 817 LGBTQ+ cancer patients: 80% had not received appropriate cancer screening for their age. The reasons were not primarily attitudinal. They reflected structural barriers: the provider did not mention screening, the patient did not have a provider for routine care, and lack of insurance. Avoidance of healthcare settings due to prior experiences of discrimination was also a significant contributing factor.

    NCI’s Cancer Currents Blog summarized the evidence clearly: there is consistent evidence that SGM people are less likely to seek care for possible cancer symptoms, and as a result their cancers may be diagnosed at more advanced stages. Later-stage diagnosis is one of the most powerful predictors of worse outcomes in most cancer types.

    Worse experiences during cancer care

    A 2025 study from the Moffitt Cancer Center published in JNCI Monographs analyzed real-world SOGI data collected at an NCI-designated comprehensive cancer center and found that SGM individuals with a history of cancer report significantly greater distress, relationship difficulties, substance use, dissatisfaction with cancer care, and lower quality of life compared with heterosexual and cisgender counterparts.

    A 2023 study in JAMA Oncology examining breast cancer in sex and gender minority groups found disparities in diagnosis, treatment, and outcomes compared to cisgender women. And a 2025 review in PMC covering breast cancer disparities in LGBTQ+ communities concluded that disparities exist from screening through survivorship and lead to measurably worse outcomes.

    The Root Cause: You Cannot Fix What You Cannot Measure

    If there is a single structural problem behind LGBTQ+ cancer disparities, it is the routine failure to ask patients who they are.

    Sexual orientation and gender identity (SOGI) data refers to the collection of patients’ sexual orientation and gender identity in clinical intake and electronic health records. Most health systems in the United States do not do this consistently or at all. When oncology teams do not know a patient is gay, bisexual, transgender, or nonbinary, they cannot screen for subgroup-specific risks, connect the patient to appropriate support services, or enroll them in research studies that could generate knowledge about their population.

    The consequences are not merely administrative. A transgender woman who presents with breast symptoms may receive different clinical attention than a cisgender woman. A gay man’s partner may not be included in care conversations in the same way as a heterosexual spouse. A nonbinary patient’s need for survivorship support that accounts for their identity may simply not be addressed.

    A 2025 JNCI Monographs paper on SOGI data collection in oncology described the problem directly: a standardized approach to collecting accurate SOGI data is critical to best serving LGBTQ+ patients’ cancer care needs, fully understanding the scale of disparities, and generating the research needed to address them. The paper called for best practices for SOGI collection and dissemination across cancer centers.

    Why SOGI data collection is harder than it sounds, and why it is still the right target Healthcare providers sometimes resist SOGI data collection out of concern that patients will find the questions intrusive or that the data will be used inappropriately. The research does not support this concern. Multiple studies have shown that most patients, including LGBTQ+ patients, are willing to disclose SOGI information when asked in a respectful, standardized clinical context, and that they consider it important for their care. The barriers are primarily on the provider and system side, not the patient side. Implementation requires: standardized, validated questions in intake workflows (the “Do Ask, Do Tell” framework from The Fenway Institute); training staff in respectful, inclusive communication; integrating SOGI fields into electronic health record systems; and using the data for clinical decision support rather than collecting it and ignoring it. None of these steps are technically complex. They require institutional commitment.

    What the Research Community Is Doing About It

    The evidence base for LGBTQ+ cancer disparities has grown substantially in the past five years, but the research infrastructure to support it has lagged behind. Several developments are beginning to address that gap.

    The Q Cancer Research Center

    In Spring 2026, the American Cancer Society funded a new Cancer Health Research Center (CHERC) at the University of Rochester: the Q Cancer Research Center. It is designed as a national center without walls, meaning its scope extends beyond a single institution.

    The Q Cancer Research Center’s funded projects specifically address three of the gaps identified above: improving the standardized collection of SOGI data in clinical settings, developing survivorship programs tailored to LGBTQ+ patients’ specific needs and identities, and training a new generation of researchers with expertise in LGBTQ+ cancer health equity. The center’s structure as a national collaborative rather than a site-specific program is designed to generate findings and tools that can be implemented broadly.

    NCI investment in SGM cancer research

    The National Cancer Institute has developed a dedicated funding opportunity for research on cancer care and outcomes in SGM cancer survivors, and launched the SGM Cancer CARE program to train 150 early-career investigators over five years. The first national conference dedicated to SGM cancer research was held in October 2023, with nearly 200 attendees, marking a recognition within the research community that this field needs its own infrastructure.

    Growing clinical recognition

    The American Society for Clinical Oncology (ASCO) has recognized SGM communities as a population experiencing health disparities and has increasingly incorporated SGM health equity into its conference programming and clinical guidance development. The Fenway Institute maintains the “Do Ask, Do Tell” SOGI data collection framework and training resources for clinical teams. The National LGBT Cancer Network provides patient navigation and provider education specifically focused on LGBTQ+ cancer care.

    What This Means for Patients and Clinicians

    For LGBTQ+ patients navigating cancer screening and care

    The disparities documented in the research are real but they are not inevitable. They are products of structural barriers, not immutable characteristics of LGBTQ+ identity. Several resources exist specifically to support LGBTQ+ patients in cancer prevention and care:

    If you have experienced discrimination or inadequate care in oncology settings because of your sexual orientation or gender identity, that experience is well-documented and not isolated. Seeking a second opinion from a provider with LGBTQ+ health expertise is a reasonable step.

    For oncology clinicians and care teams

    The single most actionable change most clinical settings can make is implementing standardized SOGI data collection at intake. The Fenway Institute’s “Do Ask, Do Tell” resources provide validated question formats and implementation guidance. Collecting this data is not sufficient on its own; care teams need to use it to inform clinical conversations, support navigation to LGBTQ+-specific resources, and report it in ways that can be aggregated for research.

    Survivorship care plans should explicitly address LGBTQ+ patients’ specific needs, including the intersection of gender-affirming hormone therapy with cancer treatment decisions, the mental health burden associated with minority stress, and the importance of including chosen family and partners in care conversations.

    For related women’s health and cancer coverage on Health Evidence Digest, see our posts on the first approved immunotherapy for ovarian cancer, cervical cancer screening guidelines for 2026, and AI-supported mammography and the MASAI trial findings.

    Sources

    ACS 2024 LGBTQ+ Cancer Special Section: American Cancer Society. Cancer Facts and Figures 2024 Special Section: Cancer in People Who Identify as Lesbian, Gay, Bisexual, Transgender, and/or Queer. cancer.org.

    ACS LGBTQ+ Report press release (2024): American Cancer Society Releases Pioneering LGBTQ+ Cancer Report. pressroom.cancer.org. May 2024.

    NCI Cancer Currents LGBTQ+ disparities: Cancer Health Disparities Among LGBTQ+ People. cancer.gov. May 2024.

    Moffitt SOGI data study (JNCI Monographs 2025): Zamani SA, Pérez-Morales J, et al. Sexual orientation and gender identity data reveals real-world cancer disparities among sexual and gender minorities at an NCI-Designated Comprehensive Cancer Center. JNCI Monographs. 2025;69:76-87. doi:10.1093/jncimonographs/lgaf017. PMC12268166.

    SOGI data collection best practices (JNCI Monographs 2025): Developing, implementing, and disseminating best practices for SOGI collection among cancer patients. JNCI Monographs. 2025;69:96. doi:10.1093/jncimono/lgaf016.

    ASCO 2024 LGBTQ+ screening abstract: Maingi S, Schabath MB, Dewald I, et al. Disparities uncovered: LGBTQ+ patients report on their cancer care journey. ASCO 2024. Abstract 1516.

    Breast cancer LGBTQ+ disparities (JAMA Oncology 2023): Eckhert E et al. Breast cancer diagnosis, treatment, and outcomes of patients from sex and gender minority groups. JAMA Oncol. 2023;9(4):473-480.

    Breast cancer LGBTQ+ review (PMC 2025): Breast Cancer Disparities in the LGBTQ+ Community. PMC12320750.

    Gallup LGBTQ+ identification data: LGBT Identification in U.S. Ticks Up to 7.6%. Gallup.

    Minority stress model reference: Meyer IH. Prejudice, Social Stress, and Mental Health in Lesbian, Gay, and Bisexual Populations. Psychol Bull. 2003.

    Do Ask, Do Tell SOGI framework: The Fenway Institute. Do Ask, Do Tell.

    ACS research grant programs: American Cancer Society Institutional Research Grants and CHERC Awards. cancer.org.

    Patient resources: National LGBT Cancer Network | GLMA Provider Directory | The Fenway Institute | NCI Cancer Screening

    Disclaimer: Health Evidence Digest provides general information about health research and cancer equity for educational purposes. This content is not a substitute for professional medical advice. Cancer screening and treatment decisions should be made in consultation with a qualified healthcare provider.